Pharmacology Biochemistry & Behavior, Vol. 17. Copyright © 1982 by Ankho International Inc. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

Index to

VOLUME 17

Pharmacology Biochemistry & Behavior, Vol. 17. Copyright © 1982 by Ankho International Inc. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 1982

SUBJECT INDEX

Abstinence syndrome, 389
  chronic administration
  dependence
  endorphins
  morphine
  naloxone
  opiates
Acetaldehyde
  Antabuse®, 1103
  blood pressure, 1103
  body weight, 807
  disulfiram, 1103
  ethanol, 1103
  food deprivation, 807
  heart rate, 1103
  photoperiod, 807
  4-methylpyrazole, 1103
  schedule-controlled responding, 807
  self-injection, 807
Acetylcholine, 419
  analgesia
  corpus striatum
  morphine
Acetylcholine release, 933
  avoidance behavior
  lesions, magnocellular forebrain nuclei
  scopolamine
Acetylcholinesterase reactivation, 1001
  conditioned avoidance
  DFP
  oximes
  PAM
  proPAM
  thermoregulation
Acetylsalicylic acid, 73
  cellular dehydration
  drinking
  hypovolemia
  indomethacin
  plasma angiotensin II
  prostaglandin E
Acoustic startle, 413
  d-amphetamine
  schizophrenia, etiology
  sensitization
  stress
Acquisition, 1055
  diazepam
  human studies
  scheduled responding
Acquisition deficits, 165
  cognition
  diazepam
  free recall
  human studies
  paired-associate learning
  serial learning
  serial position effects
ACTH
  corticotropin releasing factor (CRF), 1203
  dopamine agonists, 31
  dopamine antagonists, 31
  dopaminergic system, 31
  β-endorphin, 1203
  grooming, 31
  hypothermia, 1203
  locomotor activity, 31
  α-MSH, 1203
  naloxone, 1203
  ptosis, 1203
  reserpine, 1203
  sedation, 1203
  temperature, 1203
$ACTH_{1-24}$, 37
  deoxyglucose uptake
  footshock
  $MSH/ACTH_{4-10}$
  naloxone
$ACTH_{4-9}$ analog, 177
  active avoidance
  dose-dependent effects
  ORG-2766
  passive avoidance
Active avoidance
  $ACTH_{4-9}$ analog, 177
  amphetamine, 15
  dose-dependent effects, 177
  haloperidol, 15
  β-[Tyr^0]melanotropin-(9–18), 15
  open field, 15
  ORG-2766, 177
  passive avoidance, 177
Acute administration, 461
  antidepressants
  kindling, amygdaloid
  seizures
  subacute administration
Adenosine, 749
  cerebral cortical prisms
  dipyridamole
  morphine
  ^3H-purines release
Adenosine triphosphatase, 927
  ethanol
  postnatal exposure
  prenatal exposure
Adipsia, 249
  anorexia
  drinking
  eating
  hypothalamus
  starvation
  TRH
Adrenalectomy, 529
  corticosterone
  endocrine effects
  estradiol
  ethanol
  hamsters
  ovariectomy
Adrenergics, 1257
  catecholamines

Numbers preceded by the letter s indicate items appearing in *Dopamine Receptors and Their Behavioral Correlates*, Suppl. 1, Vol. 17, 1982.

hippocampus
in vitro studies
learning and memory
long-term potentiation
neuroleptics
Affective behavior, 381
amphetamine psychosis
animal models
chronic administration
defensive flight
Age, 1187
blood-brain barrier
delta sleep-inducing peptide (DSIP)
DSIP analogs
radioimmunoassay
Age differences, 1037
ethanol
intoxication
withdrawal
Aggregation toxicity, 467
catecholamines
p-chloroamphetamine
environmental effects
stress
Aggression
anxiety, 623
desipramine, 377
electroshock, 377
lesions, septum, 623
lithium, 377
neurotoxins, 623
social interaction, 623
Aggression inhibition, 147
brain stimulation, electrical
DU27716
hypothalamus
phenylpiperazines
Aggression, shock-induced, 945
p-chlorphenylalanine
pressing responses
serotonin
Aggressive behavior
hyperactivity, 503
isolation housing, 691
isolation syndrome, 1291
opiate antagonists, 691
phencyclidine, 503
phenylethylamine, 1291
social behavior, 691
stress, 1291
tyramine, 1291
Aging mice, 313
benzodiazepine
cholinergic receptors
environmental enrichment
passive avoidance
Albino rats, 1313
ethyl alcohol
photic evoked potentials
superior colliculus
visual cortex
Alcohol
brain reward systems, 233
brain stimulation, 1093
defecation, 961
drug discrimination, 1093
drugs of abuse, 233
emotionality, 961
genetic differences, 961
open field reactivity, 961
reward, 1093
sex differences, 961
Alcohol preference
β-carbolines, 831
cohabitation, 1097
drinking, 763, 831
ICV infusion, 831
intravenous infusion, 763
lactation, 1097
4-methylpyrazole, 763
post-lactation, 1097
pregnancy, 1097
Aldehyde dehydrogenase, 91
aldehyde oxidase
eclampsia
flurothyl
pregnancy, mice
pyridoxal kinase
pyridoxamine phosphate oxidase
seizure susceptibility
Aldehyde oxidase, 91
aldehyde dehydrogenase
eclampsia
fluorthyl
pregnancy, mice
pyridoxal kinase
pyridoxamine phosphate oxidase
seizure susceptibility
Ambulatory activity
apomorphine, 1251
circadian variation, 1251
clonidine, 519
drinking, 519
guanfacine, 519
hypertension, 519
methamphetamine, 1251
Amino acids, 939
obesity, genetic
serotonin
tryptophan
Zucker rats
Aminoglycosides, 363
hair cells
ototoxicity
schooling behavior
streptomycin
tadpoles
Amitriptyline, 1221
blood pressure
cardiovascular system
heart rate
iprindole
trazodone
Amnesia, 187
anisomycin
catecholamine biochemistry
cycloheximide
protein synthesis inhibitors
Amphetamine
active avoidance, 15
anorexia, 99, 255, 271
antagonism, 671
apomorphine, 375, 1305
attentional deficit disorder, 5
behavioral augmentation, 547
brain catecholamine levels, 271
brain stimulation, 431
caffeine, 613
catecholamines, 255
circling behavior, 431
conditioned taste aversion, 1129
developing rats, 5
discriminative stimulus, 603, 671
dopamine, 1305
dopamine autoreceptors, 375
dopaminergic system, 431
eating, 99, 255
electroconvulsive shock, 375
fenfluramine, 99
GABA, 99

generalization, 671
gentically obese mice, 271
gerbils, 1305
hallucinogens, 603
haloperidol, 15, 613
6-hydroxydopamine, 5, 99
hyperactivity, 5
hyperglycemia, 271
hyperkinesis, 5
hyperphagia, 271
intracerebral electrochemistry, 445
log survivor analysis, 255
locomotor activity, 99, 445, 547
metergoline, 99
methoxyphenylisopropylamines, 603
microstructural analysis, 255
neurotransmitters, 1305
nucleus accumbens, 445
obesity, 271
open field, 15
phenylisopropylamines, 603
pigeons, 671
pimozide, 431, 613, 1305
propranolol, 255
repeated administration, 547
route of administration, 1129
saccharin, 1129
self-biting, 613
social behavior, 1305
sterotypy, 547, 1305
striatum, 445
structure-activity relationships, 603
substantia nigra, 431
sympatomimetics, 547
β-[Tyr^9]melanotropin-(9–18)
d-Amphetamine
acoustic strartle, 413
1-desamino-8-D-arginine, 1123
fluphenazine decanoate, 25
locomotor activity, 25
matching-to-sample, 1123
memory, short-term, 1123
pigeons, 1123
schizophrenia, etiology, 413
scopolamine, 1123
sensitivity, 25
sensitization, 413
serum prolactin, 25
stress, 413
vasopressin analogues, 1123
Amphetamine psychosis, 381
affective behavior
animal models
chronic administration
defensive flight
Amygdala central nucleus, 217
enkephalin analogs
heart rate conditioning
opiate receptors
rabbits
Analgesia
acetylcholine, 419
body temperature, 733
cardiac rates, 733
cold water swims, 1175
collateral inhibition, 1175
corpus striatum, 419
dog, conscious, 733
dose-response, 757, 1213
formalin test, 1213
goldfish, 757
MIF-1, 757
morphine, 419, 757, 1161, 1175
morphine tolerance, 1213
naloxazone, 1175
naloxone, 757
naltrexone, 733
nicotine, 733
prenatal exposure, 1161
pupillary diameter, 733
respiratory rates, 733
tail-flick test, 1161, 1213
Analgesia, stress-induced, 1019
endogenous opiates
inescapable shock
learned helplessness
morphine hyperreactivity
naltrexone
Angiotensin, 741
blood pressure, arterial
crinia-angiotensin II
drinking
pigeons
rats
Anhedonia paradigm refinements, 987
clozapine
fluphenazine
pimozide
Animal models, 381
affective behavior
amphetamine psychosis
chronic administration
defensive flight
Anisomycin, 187
amnesia
catecholamine biochemistry
cycloheximide
protein synthesis inhibitors
Anorexia
adipsia, 249
amphetamine, 99, 255, 271
brain catecholamine levels, 271
catecholamine agonists, 1135
catecholamines, 255
consummatory behavior, 1135
drinking, 249
eating, 99, 249, 255, 539
fenfluramine, 99
GABA, 99
genetically obese mice, 271
hallucinogens, 539
6-hydroxydopamine, 99
hyperglycemia, 271
hyperphagia, 271, 539
hypothalamus, 249
locomotor activity, 99
log survivor analysis, 255
metergoline, 99
microstructural analysis, 255
monoamine inhibitors, 1135
obesity, 271
propranolol, 255
strarvation, 249
TRH, 249
Antabuse®, 1103
acetaldehyde
blood pressure
disulfiram
ethanol
heart rate
4-methylpyrazole
Antagonism
amphetamine, 671
discriminative stimulus, 223, 671
generalization, 671
morphine, 223
naloxone, 223
pigeons, 223, 671
tolerance, 223

Antemortem violence, 171
  human studies
  postmortem plasma LH
Antianxiety drugs
  buspirone, s25, s37
  comparative neuropharmacology, s37
  dopamine, s25
  pharmacotherapy, s25
Anticholinergics, 85
  atropine
  benactyzine
  DRL schedule
  rhesus monkey
  schedule-controlled behavior
  scopolamine
Anticonflict effects, 1
  drinking
  isoproterenol
Antidepressants
  acute administration, 461
  kindling, amygdaloid, 461
  muricide, 847
  seizures, 461
  serotonin, 847
  subacute administration, 461
Antipsychotics, 1049
  clozapine
  collateral behavior
  drinking
  eating
  haloperidol
  operant behavior
  rabbits
  schedule-induced behavior
  scheduled responding
  thiothixene
Anxiety
  aggression, 623
  apomorphine, 59
  conditioned suppression, 59
  diazepam, 59
  lesions, septum, 623
  locomotor activity, 59
  neurotoxins, 623
  social interaction, 623
Anxiolytics
  benzodiazepines, 645
  conditioned defensive burying, 359
  conflict test, 645
  diazepam, 359
  ethanol, 645
  GABAergic system, 359
  meprobamate, 645
  phenobarbital, 645
  picrotoxin, 359
  squirrel monkeys, male, 645
Apparatus, 823
  tethering system for primate catheterization
Appetitive conditioning, 1281
  apomorphine
  attention deficit disorder
  dopamine depletion
  6-hydroxydopamine
  hyperactivity
Appetitive tasks, 909
  aversive tasks
  learning
  memory, long-term
  sodium barbitone
  Y-maze
Apomorphine
  ambulatory activity, 1251
  amphetamine, 375, 1305
  anxiety, 59
  appetitive conditioning, 1281
  attention deficit disorder, 1281
  circadian variation, 1251
  circling behavior, 1233
  climbing behavior, 651
  conditioned suppression, 59
  consolidation, 11
  diazepam, 59
  dopamine, 1305
  dopamine autoreceptors, 375
  dopamine depletion, 1281
  dopamine receptors, 967
  dopaminergic action, 393
  drug discrimination, 393
  electroconvulsive shock, 375
  GABA, 651
  gerbils, 1305
  glycoprotein synthesis, 11
  haloperidol, 393
  hippocampus, 11
  6-hydroxydopamine, 1233, 1281
  hyperactivity, 1281
  indomethacin, 1233
  intracranial self-stimulation, 1015
  in vivo studies, 651
  lesions, nucleus accumbens, 1015
  lesions, 6-OHDA, 1015
  locomotor activity, 59, 967
  methamphetamine, 1251
  methysergide, 393
  muscimol, 651
  neurotransmitters, 1305
  picrotoxin, 651
  pimozide, 967, 1305
  prostaglandins, 1233
  quantitative behavioral analysis, 873
  quipazine, 393
  serotonin, 393
  social behavior, 1305
  stereotyped behavior, 873
  stereotypy, 967, 1305
  strain differences, 967
Apomorphine antagonism, 1309
  benzamides
  butyrophenones
  locomotor activity
  neuroleptics
  phenothiazines
  rhesus monkey
Apomorphine stereotypy, 1115
  locomotor activity
  strain differences
  striatal dopamine receptors
N-methyl-D-Aspartate, 715
  glutamic acid diethylester
  kainic acid
  morphine
  muscular rigidity
  quisqualic acid
  striatum
Aspartic acid, 1265
  core temperature
  drinking
  eating
  urine outflow
Ataxia, 1165
  chlordiazepoxide
  exploratory behavior
  locomotor activity
  muscimol
  muscle relaxation
  naloxone
  picrotoxin
Atropine
  anticholinergics, 85
  benactyzine, 85

benztropine, 851
diphenhydramine, 851
DRL schedule, 85
haloperidol, 851
rhesus monkey, 85
schedule-controlled behavior, 85
scopolamine, 85
self-stimulation, 851
Atropine methyl nitrate, 863
cholinergic blockade
diet palatability
hunger
sham feeding
Attention, 915
cigarette smoking
human studies
nicotine
visual evoked response
Attention deficit disorder
amphetamine, 5
apomorphine, 1281
appetitive conditioning, 1281
developing rats, 5
dopamine depletion, 1281
6-hydroxydopamine, 5, 1281
hyperactivity, 5, 1281
hyperkinesis, 5
Avoidance, 1245
cue discrimination
neuroleptic treatment
pimozide
response-choice discrimination
Avoidance behavior
acetylcholine release, 933
H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
lesions, magnocellular forebrain nuclei, 933
open-field, 633
scopolamine, 933
Avoidance suppression, 131
haloperidol
repeated administration
Aversive tasks, 909
appetitive tasks
learning
memory, long-term
sodium barbitone
Y-maze

Baboons
cocaine, 823
hashish, 209
primates, 823
self-administration, 823
social behavior, male baboons, 209
tether restraint for catheterization, 823
Baclofen
catalepsy, haloperidol-induced, 855
clonidine, 1207
extinction, 1207
GABA receptors, 855
haloperidol, 1207
intracranial self-stimulation, 1207
methocarbamol, 1207
metoclopramide, 1207
prazosin, 1207
response decrement patterns, 1207
BASIC, 583
behavioral pharmacology
operant research
TRS-80 microcomputer
Behavior, 111
blood alcohol levels
ethanol
oral intubation
pregnancy
squirrel monkeys
Behavioral augmentation, 547
amphetamine
locomotor activity
repeated administration
stereotypy
sympathomimetics
Behavioral depression, 1271
bradycardia
endogenous opioid-like peptide
hibernation "trigger"
hypophagia
hypothermia
opioid antagonists
plasma albumin fraction
rhesus monkey
Behavioral effects, 703
catalepsy
β-endorphin
morphine
opiates
Behavioral pharmacology, 583
BASIC
operant research
TRS-80 microcomputer
Behavioral side-effects, 1225
body weight
cancer chemotherapy
drinking
glucocorticoids
gonads
nociception
pituitary-adrenal axis
prednisolone
Behavioral toxicity, 399
cardioglycosides
clonidine
digitoxin
propranolol
Benactyzine, 85
anticholinergics
atropine
DRL schedule
rhesus monkey
schedule-controlled behavior
scopolamine
Benzamides, 1309
apomorphine antagonism
butyrophenomes
locomotor activity
neuroleptics
phenothiazines
rhesus monkey
Benzodiazepines
aging mice, 313
anxiolytic agents, 645
caffeine, 481
chlordiazepoxide, 709
cholinergic receptors, 313
conflict test, 645
drinking, 481
drug discrimination, 709
drug experience effects, 43
environmental enrichment, 313
ethanol, 645
GABA, 973
Geller-Selfter conflict test, 43
5-hydroxytryptamine, 973
hypodipsia, 481
individual variability, 43
locomotor activity, 973
meprobamate, 645
muscimol, 973
oxazepam, 43
passive avoidance, 313

phenobarbital, 645
rate dependency, 43
satiety, 481
squirrel monkeys, male, 645
tolerance, 43
triazolopyridazines, 709
ventral tegmental nuclei of Gudden, 973
Benzodiazepine antagonists, 457
3-carbomethoxy-β-carboline
CGS 8216
diazepam
RO 15-1788
seizures
Benzodiazepine receptors, 367
diazepam
tofizopam
Benztropine, 851
atropine
diphenhydramine
haloperidol
self-stimulation
Bethanechol, 727
drinking
parasympathomimetic agents
renin-angiotensin system
Biochanin A, 405
dietary supplements
ferulic acid
quail
sexual behavior, birds
Blood alcohol levels, 111
behavior
ethanol
oral intubation
pregnancy
squirrel monkeys
Blood-brain barrier
age, 1187
central nervous system, 1199
cerebrospinal fluid, 1009
column chromatography, 1009
delta sleep-inducing peptide (DSIP), 1187
dogs, 1009
DSIP, 1009
DSIP analogs, 1187
α-MSH, 1199
protein binding, 1009
radioimmunoassay, 1187
^{99m}Tc-sodium pertechnetate, 1199
Blood levels, 183
body temperature
Implantable Nicotine Reservoir
nicotine
sustained release
Blood pressure
acetaldehyde, 1103
amitriptyline, 1221
Antabuse®, 1103
cardiovascular system, 1221
disulfiram, 1103
ethanol, 1103
heart rate, 1103, 1221
iprindole, 1221
4-methylpyrazole, 1103
trazodone, 1221
Blood pressure, arterial, 741
angiotensin
crinia-angiotensin II
drinking
pigeons
rats
Body temperature
analgesia, 733
blood levels, 183
cardiac rates, 733
diarrhea, 885
diisopropyl phosphorofluoridate, 885
dog, conscious, 733
fixed-ratio responding, 885
generalization, 885
hypothermia, ethanol-induced, 119
Implantable Nicotine Reservoir, 183
locomotor activity, 885
naloxone, 119
naltrexone, 733
nicotine, 183, 733
pupillary diameter, 733
respiratory rates, 733
selective breeding, 885
stress, 119
sustained release, 183
Body weight
acetaldehyde, 807
behavioral side-effects, 1225
cancer chemotherapy, 1225
drinking, 1225
food deprivation, 807
glucocorticoids, 1225
gonads, 1225
nociception, 1225
photoperiod, 807
pituitary-adrenal axis, 1225
prednisolone, 1225
schedule-controlled responding, 807
self-injection, 807
Bradycardia, 1271
behavioral depression
endogenous opioid-like peptides
hibernation "trigger"
hypophagia
hypothermia
opioid antagonists
plasma albumin fraction
rhesus monkey
Brain
amygdala, 249, 461, 1111, 1193
amygdala central nucleus, 217
basal ganglia, 77, 1061
caudate nucleus, s43, 797, 1061
cerebellum, 37, 313, 569, 1067
cerebral cortex, 313, 431, 749, 933
cerebral ventricle, 1271
corpus striatum, 283, 419
cortex, 37, 461, 813, 1061, 1193
diagonal band of Broca, 841
dorsal noradrenergic bundle, 435, 639
dorsal premamillary nucleus, 797
dorsomedial nucleus of thalamus, 797
entorhinal cortex, 77
frontal cortex, 77, 677
globus pallidus, 249
hippocampus, 11, 37, 193, 203, 313, 797, 813
hypothalamus, 37, 147, 271, 677, 721, 797, 1093
lateral habenula, 841
lateral hypothalamus, 249
lateral preoptic area, 797
limbic forebrain, 1115
magnocellular forebrain nuclei, 933
medial forebrain bundle, 769, 841
medial hypothalamus, 249
medial raphe nucleus, 597
medial septal nucleus, 797
mesencephalic reticular formation, 797
mesocortex, s1
mesolimbus, s1
nigrostriatum, s1
nucleus accumbens, 193, 249, 283, 797, 1015
nucleus accumbens septum, 579
olfactory bulb, 37
parietal cortex, 797

pituitary, 1067
pons-medulla, 1193
raphe nuclei, 435
septum, 77, 297, 623
striatum, 313, 445, 715, 1115, 1193, 1233
substantia nigra, 249, 431, 1061
superior colliculus, 1313
tectum, 37
thalamus, 37, 677
ventral noradrenergic bundle, 619
ventral tegmental nuclei of Gudden, 973
ventral tegmentum, 841, 901
ventromedial hypothalamus, 1141
visual cortex, 1313
Brain catecholamine levels, 271
amphetamine
anorexia
genetically obese mice
hyperglycemia
hyperphagia
obesity
Brain development, 473
corticosteroids
neonates, rats
radial maze
T-maze
triamocinolone acetonide
Brain indoleamines, 857
estrous cycle
ovariectomized rats
paced coital stimulation
Brain reward systems
alcohol, 233
drugs of abuse, 233, 239
opiates, 239
Brain slice technique, 699
chronic treatment
dopamine receptors
opiate receptors
phencyclidine receptors
Brain stimulation
alcohol, 1093
amphetamine, 431
circling behavior, 431
dopaminergic system, 431
drug discrimination, 1093
pimozide, 431
reward, 1093
substantia nigra, 431
Brain stimulation, electrical, 147
aggression inhibition
DU 27716
hypothalamus
phenylpiperazines
Buspirone
antianxiety drugs, s25, s37
comparative neuropharmacology, s37
dopamine, s25
pharmacotherapy, s25
γ-Butyrolacetone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417), 797
cholinergic mechanisms
hypothalamus
pentobarbital antagonists
sleep
TRH
Butyrophenones, 1309
apomorphine antagonism
benzamides
locomotor activity
neuroleptics
phenothiazines
rhesus monkey
Caffeine
amphetamine, 613
benzodiazepines, 481
drinking, 481
early development, 137
haloperidol, 613
hypodipsia, 481
jewel fish, 137
pimozide, 613
satiety, 481
self-biting, 613
spatial behavior, 137
Cancer anorexia, 1043
p-chlorophenylalnine
dopamine
eating
5-hydroxyindoleacetic acid
norepinephrine
serotonin
tryptophan
Cancer chemotherapy, 1225
behavioral side-effects
body weight
drinking
glucocorticoids
gonads
nociception
pituitary-adrenal axis
prednisolone
Carbachol-induced fighting, 371
cats
cholinergic neurons
depressants
morphine
β-Carbolines, 831
alcohol preference
drinking
ICV infusion
3-Carbomethoxy-β-carboline, 457
benzodiazepine antagonists
CGS 8216
diazepam
RO 15-1788
seizures
Cardiac rates, 733
analgesia
body temperature
dog, conscious
naltrexone
nicotine
pupillary diameter
respiratory rates
Cardiac tissue, transplant, 1285
drug effects
microvasculature
Cardioglycosides, 399
behavioral toxicity
clonidine
digitoxin
propranolol
Cardiovascular activity, 1301
dog
Leu-enkephalin
MIF-1
naloxone
Cardiovascular reflex, 19
D-Ala^2-Met^5-enkephalinamide
morphine
motor activity
phenyldiguanide
pulmonary J-receptors
pulmonary opiate receptors
vagal afferents
Cardiovascular system, 1221
amitriptyline

blood pressure
heart rate
iprindole
trazodone
Castration, 681
flupenthixol
haloperidol
luteinizing hormone
testosterone
Catalepsy
behavioral effects, 703
β-endorphin, 703
estrogen, 1027
haloperidol, 1027
morphine, 703
neuroleptics, 1027
opiates, 703
Catalepsy, haloperidol-induced, 855
baclofen
GABA receptors
Catecholamine agonists, 1135
anorexia
consummatory behavior
monoamine inhibitors
Catecholamine biochemistry, 187
amnesia
anisomycin
cycloheximide
protein synthesis inhibitors
Catecholamine excretion, 555
cortisol excretion
human studies
response consistency
sex differences
stress
Catecholamines
adrenergics, 1257
aggregation toxicity, 467
amphetamine, 255
anorexia, 255
eating, 255
p-chloroamphetamine, 467
environmental effects, 467
hippocampus, 1257
in vitro studies, 1257
learning and memory, 1257
log survivor analysis, 255
long-term potentiation, 1257
microstructural analysis, 255
neuroleptics, 1257
propranolol, 255
stress, 467
Cats
carbachol-induced fighting, 371
cholinergic neurons, 371
cross-tolerance, 589
depressants, 371
β-endorphin, 1317
limb-flicks, 589
lithium, 1317
LSD, 589
morphine, 371
morphine-induced behavior, 297
naloxone, 297
opiate receptors, 297, 1317
opioid peptides, 297
psychomotor excitation, 1317
septum, 297
synergism, 589
tactile stimulus, 589
Cellular dehydration, 73
acetylsalicylic acid
drinking
hypovolemia
indomethacin
plasma angiotensin II
prostaglandin E
Central acting drugs, 425
Sidman avoidance response
strain differences
Central nervous system, 1199
blood-brain barrier
α-MSH
^{99m}Tc-sodium pertechnetate
Cerebellum
corticosterone, 1067
cyclic AMP
cyclic GMP
ethanol, 569
growth hormone, 1067
hypnotic effects, 569
inbred strains, mice, 569
pituitary, 1067
prolactin, 1067
Purkinje neurons, 569
righting reflex, 569
stress, 1067
Cerebral cortical prisms, 749
adenosine
dipyridamole
morphine
^{3}H-purines release
Cerebrospinal fluid, 1009
blood-brain barrier
column chromatography
dogs
DSIP
protein binding
CGS 8216, 457
benzodiazepine antagonists
3-carbomethoxy-β-carboline
diazepam
RO 15-1788
seizures
Characterization, 1193
N-Tyr-MIF-1 binding sites
Tyr-MIF-1 receptors
Chicks, 893
memory
L-prolyl-L-leucyl-glycineamide
Chlordiazepoxide
ataxia, 1165
benzodiazepines, 709
N-demethylchlordiazepoxide, 141
drug discrimination, 709
drug interactions, 141
ethanol, 1239
ethanol-induced sleep time, 141
exploratory behavior, 1165
locomotor activity, 1165
muscimol, 1165
muscle relaxation, 1165
naloxone, 1165
naltrexone, 921
physical dependence, 1239
picrotoxin, 1165
thirst, hypervolemic, 921
thirst, osmotic, 921
tolerance, 1239
triazolopyridazines, 709
withdrawal, 1239
p-Chloroamphetamine, 467
aggregation toxicity
catecholamines
environmental effects
stress
p-Chlorophenylalinine
aggression, shock-induced, 945
cancer anorexia, 1043
dopamine, 1043

eating, 1043
5-hydroxyindoleacetic acid, 1043
medial raphe nucleus, 597
norepinephrine, 1043
pressing responses, 945
self-stimulation, 597
serotonin, 597, 945, 1043
time course analysis, 597
tryptophan, 1043
Chlorpromazine, 385
continuous avoidance
head-poke response
Cholinergic blockade, 863
atropine methyl nitrate
diet palatability
hunger
sham feeding
Cholinergic mechanisms, 797
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417)
hypothalamus
pentobarbital antagonists
sleep
TRH
Cholinergic neurons, 371
carbachol-induced fighting
cats
depressants
morphine
Cholinergic receptors
aging mice, 313
benzodiazepine, 313
depression, 159
environmental enrichment, 313
imipramine, 159
passive avoidance, 313
serotonin, 159
suicide, 159
Chronic administration
abstinence syndrome, 389
affective behavior, 381
amphetamine psychosis, 381
animal models, 381
defensive flight, 381
dependence, 389
morphine, 389
motor activity, 489
naloxone, 389
narcotics, 489
opiates, 389
supersensitivity, 489
Chronic ethanol, 629
estrous cycle, female rats
ovarian function
pregnant rats
vaginal patency, 629
Chronic treatment, 699
brain slice technique
dopamine receptors
opiate receptors
phencyclidine receptors
Cigarette smoking
attention, 915
human studies, 155, 523, 915
nicotine, 915
schedule-induced behavior, 523
self-administration, 155, 523
tobacco, 155
visual evoked response, 915
Circadian rhythms, 511
DSIP
neurotransmitters
plasma proteins
Circadian variation, 1251
ambulatory activity
apomorphine
methamphetamine
Circling behavior
amphetamine, 431
apomorphine, 1233
brain stimulation, 431
dopaminergic system, 431
6-hydroxydopamine, 1233
indomethacin, 1233
pimozide, 431
prostaglandins, 1233
substantia nigra, 431
Climbing behavior, 651
apomorphine
GABA
in vivo studies
muscimol
picrotoxin
Clonidine
ambulatory activity, 519
baclofen, 1207
behavioral toxicity, 399
cardioglycosides, 399
digitoxin, 399
drinking, 519
extinction, 1207
guanfacine, 519
haloperidol, 1207
hypertension, 519
intracranial self-stimulation, 1207
methocarbamol, 1207
methylxanthines, 655
metoclopramide, 1207
naloxone, 655
prazosin, 1207
propranolol, 399
response decrement patterns, 1207
withdrawal syndrome, 655
Clozapine
anhedonia paradigm refinements, 987
antipsychotics, 1049
collateral behavior, 1049
drinking, 1049
eating, 1049
fluphenazine, 987
haloperidol, 1049
operant behavior, 1049
pimozide, 987
rabbits, 1049
schedule-induced behavior, 1049
scheduled responding, 1049
thiothixene, 1049
Coca, 1087
cocaine
lethality
Cocaine
baboons, 823
coca, 1087
haloperidol, 1295
lesions, 6-OHDA, 901
lesions, ventral tegmental area, 901
lethality, 1087
physostigmine, 1295
primates, 823
procaine, 1295
self-administration, 823, 901, 1295
tether restraint for catheterization, 823
Cognition, 165
acquisition deficits
diazepam
free recall
human studies
paired-associate learning
serial learning
serial position effects

Cohabitation, 1097
alcohol preference
lactation
post-lactation
pregnancy
Cold water swims, 1175
analgesia
collateral inhibition
morphine
naloxazone
Collateral behavior, 1049
antipsychotics
clozapine
drinking
eating
haloperidol
operant behavior
rabbits
schedule-induced behavior
scheduled responding
thiothixene
Collateral inhibition, 1175
analgesia
cold water swims
morphine
naloxazone
Column chromatography, 1009
blood-brain barrier
cerebrospinal fluid
dogs
DSIP
protein binding
Comparative neuropharmacology, s37
antianxiety drugs
buspirone
Concurrent schedule
drinking, 341
eating, 341
ethanol reinforced responding, 333
fixed-ratio, 341
food deprivation, 341
phencyclidine, 341
rhesus monkeys, 341
satiety, 341
self-administration, 341
sucrose, 333
Conditioned avoidance, 1001
acetylcholinesterase reactivation
DFP
oximes
PAM
proPAM
thermoregulation
Conditioned defensive burying, 359
anxiolytics
diazepam
GABAergic system
picrotoxin
Conditioned drug effects, 695
drug associations
hypothermia
lithium chloride
pentobarbital
Conditioned suppression, 59
anxiety
apomorphine
diazepam
locomotor activity
Conditioned taste aversion
amphetamine, 1129
desipramine, 435
dexamethasone, 305
fluoxetine, 435
lesions, dorsal noradrenergic bundle, 435
lesions, raphe nuclei, 435
lithium, 435
nausea, 305
pretreatment effect, 435
radiation and behavior, 305
route of administration, 1129
saccharin, 1129
Conditioned taste preference, 609
ethanol dependence
withdrawal syndrome
Conflict test, 645
anxiolytic agents
benzodiazepines
ethanol
meprobamate
phenobarbital
squirrel monkeys, male
Consolidation, 11
apomorphine
glycoprotein synthesis
hippocampus
Consummatory behavior, 1135
anorexia
catecholamine agonists
monoamine inhibitors
Continuous avoidance, 385
chlorpromazine
head-poke response
Core temperature, 1265
aspartic acid
drinking
eating
urine outflow
Corpus striatum
acetylcholine, 419
analgesia, 419
hypokinesia, 283
locomotion, 283
morphine, 419
nucleus accumbens, 283
reserpine, 283
Cortical neurons, 813
Met-enkephalin
ethanol
hippocampal pyramidal neurons
naloxone
opiates
salsolinol
tetrahydroisoquinolines
tetrahydropapaveroline
Corticosteroids
brain development, 473
dysphoria, 107
neonates, rats, 473
opiate analgesics, 107
radial maze, 473
self-administration, 107
T-maze, 473
triamocinolone acetonide, 473
Corticosterone
adrenalectomy, 529
cerebellum, 1067
cyclic AMP, 1067
cyclic GMP, 1067
emotionality, 1077
endocrine effects, 529
ergot drugs, 837
estradiol, 529
ethanol, 529
growth hormone, 837, 1067
hamsters, 529
lactation, 837
locomotor activity, 1077
luteinizing hormone, 837
open field, 1077
ovariectomy, 529

pituitary, 1067
prenatal nicotine, 1077
prolactin, 837, 1067
rearing, 1077
sex differences, 1077
stress, 1067
Corticotropin releasing factor (CRF), 1203
ACTH
β-endorphin
hypothermia
α-MSH
naloxone
ptosis
reserpine
sedation
temperature
Cortisol excretion, 555
catecholamine excretion
human studies
response consistency
sex differences
stress
Crinia-angiotensin II, 741
angiotensin
blood pressure, arterial
drinking
pigeons
rats
Cross-tolerance, 589
cats
limb-flicks
LSD
synergism
tactile stimulus
Cue discrimination, 1245
avoidance
neuroleptic treatment
pimozide
response-choice discrimination
Cyclic AMP
cerebellum, 1067
corticosterone, 1067
cyclic GMP, 1067
growth hormone, 1067
memory, 677
passive avoidance, 677
pituitary, 1067
prolactin, 1067
Rolipram, 677
stress, 1067
Cyclic GMP, 1067
cerebellum
corticosterone
cyclic AMP
growth hormone
pituitary
prolactin
stress
Cycloheximide, 187
amnesia
anisomycin
catecholamine biochemistry
protein synthesis inhibitors

Defecation, 961
alcohol
emotionality
genetic differences
open field reactivity
sex differences
Defensive fighting, 451
footshock
GABA
Defensive flight, 381
affective behavior
amphetamine phychosis
animal models
chronic administration
Delta sleep-inducing peptide (DSIP)
age, 1187
blood-brain barrier, 1009, 1187
cerebrospinal fluid, 1009
column chromatography, 1009
dogs, 1009
DSIP analogs, 1187
protein binding, 1009
radioimmunoassay, 1187
N-Demethylchlorodiazepoxide, 141
chlordiazepoxide
drug interactions
ethanol-induced sleep time
2-Deoxy-D-glucose, 955
drinking
eating
glucoprivation
water deficits
^{14}C-2-Deoxyglucose autoradiography, 841
diagonal band of Broca
lateral habenula
medial forebrain bundle
pimozide
reinforcement
self-stimulation
ventral tegmentum
Deoxyglucose uptake, 37
$ACTH_{1-24}$
footshock
$MSH/ACTH_{4-10}$
naloxone
2-Deoxyglucose, 1145
ethanolamine-O-sulfate
GABA
glucoprivic feeding
insulin
Dependence, 389
abstinence syndrome
chronic administration
endorphins
morphine
naloxone
opiates
Depressants
carbachol-induced fighting, 371
cats, 371
cholinergic neurons, 371
cholinergic receptors, 159
imipramine, 159
morphine, 371
serotonin, 159
suicide, 159
1-Desamino-8-D-arginine (DDAVP), 1123
d-amphetamine
matching-to-sample
memory, short-term
pigeons
scopolamine
vasopressin analogues
Desipramine
aggression, 377
conditioned taste aversion, 435
electroshock, 377
fluoxetine, 435
lesions, dorsal noradrenergic bundle, 435
lesions, raphe nuclei, 435
lithium, 377, 435
pretreatment effect, 435
Developing rats, 5
amphetamine
attentional deficit disorder
6-hydroxydopamine

hyperactivity
hyperkinesis
Development, 659
estrous cycle
malnutrition, postnatal
malnutrition, prenatal
sexual behavior
Dexamethasone, 305
conditioned taste aversion
nausea
radiation and behavior
Diagonal band of Broca, 841
^{14}C-2-deoxyglucose autoradiography
lateral habenula
medial forebrain bundle
pimozide
reinforcement
self-stimulation
ventral tegmentum
Diarrhea, 885
body temperature
diisopropyl phosphorofluoridate
fixed-ratio responding
generalization
locomotor activity
selective breeding
Diazepam
acquisition, 1055
acquisition deficits, 165
anxiety, 59
anxiolytics, 359
apomorphine, 59
benzodiazepine antagonists, 457
benzodiazepine receptors, 367
3-carbomethoxy-β-carboline, 457
CGS 8216, 457
cognition, 165
conditioned defensive burying, 359
conditioned suppression, 59
drug discrimination, 1171
drug stimulus complex, 1171
free recall, 165
GABAergic system, 359
human studies, 165, 1055
locomotor activity, 59
paired-associate learning, 165
picrotoxin, 359
RO 15-1788, 457
scheduled responding, 1055
seizures, 457
serial learning, 165
serial position effects, 165
tofizopam, 367
Dietary supplements, 405
biochanin A
ferulic acid
quail
sexual behavior, birds
Diet palatability, 863
atropine methyl nitrate
cholinergic blockade
hunger
sham feeding
Digitoxin, 399
behavioral toxicity
cardioglycosides
clonidine
propranolol
Diisopropyl phosphorofluoridate (DFP)
acetylcholinesterase reactivation, 1001
body temperature, 885
conditioned avoidance, 1001
diarrhea, 885
fixed-ratio responding, 885
generalization, 885
locomotor activity, 885
oximes, 1001
PAM, 1001
proPAM, 1001
selective breeding, 885
thermoregulation, 1001
Diphenhydramine, 851
atropine
benztropine
haloperidol
self-stimulation
Diprenorphine, 347
naloxone
narcotic antagonists
spontaneous activity
Dipyridamole, 749
adenosine
cerebral cortical prisms
morphine
^{3}H-purines release
Discriminative stimulus, 671
amphetamine
antagonism
generalization
pigeons
Discriminative stimulus properties
amphetamines, 603
antagonism, 223
hallucinogens, 603
methoxyphenylisopropylamines, 603
morphine, 223
naloxone, 223
phenylisopropylamines, 603
pigeons, 223
structure-activity relationships, 603
tolerance, 223
Disulfiram, 1103
acetaldehyde
Antabuse®
blood pressure
ethanol
heart rate
4-methylpyrazole
Dog
analgesia, 733
blood-brain barrier, 1009
body temperature, 733
cardiac rates, 733
cardiovascular activity, 1301
cerebrospinal fluid, 1009
column chromatography, 1009
DSIP, 1009
Leu-enkephalin, 1301
MIF-1, 1301
naloxone, 1301
naltrexone, 733
nicotine, 733
protein binding, 1009
pupillary diameter, 733
respiratory rates, 733
Dopamine
amphetamine, 1305
antianxiety drugs, s25
apomorphine, 1305
buspirone, s25
cancer anorexia, 1043
p-chlorophenylalanine, 1043
eating, 1043
extinction, 769
fucose, 203
fucosyltransferase, 203
GDP-fucose, 203
gerbils, 1305
glycoprotein synthesis, 203
hippocampus, 203

5-hydroxyindoleacetic acid, 1043
neuroleptics, 769
neurotransmitters, 1305
norepinephrine, 1043
pharmacotherapy, s25
pimozide, 769, 1305
reinforcement, 769
self-stimulation, 769
serotonin, 1043
social behavior, 1305
stereotypy, 1305
tryptophan, 1043
Dopamine agonists
ACTH, 31
dopamine antagonists, 31
dopamine autoreceptors, 1
dopaminergic system, 31
grooming, 31
locomotor activity, 31
Dopamine autoreceptors
amphetamine, 375
apomorphine, 375
dopamine agonists, s1
electroconvulsive shock, 375
Dopamine binding sites, s43
iron deficiency
Dopamine depletion, 1281
apomorphine
appetitive conditioning
attention deficit disorder
6-hydroxydopamine
hyperactivity
Dopamine receptor agonists, s11
structure-activity relationships
Dopamine receptors
apomorphine, 967
brain slice technique, 699
chronic treatment, 699
locomotor activity, 967
motor activity, 951
nomifensine, 951
opiate receptors, 699
phencyclidine receptors, 699
pimozide, 967
stereotypy, 967
strain differences, 967
Dopaminergic action, 393
apomorphine
drug discrimination
haloperidol
methysergide
quipazine
serotonin
Dopaminergic agents, s21
stress
time
Dopaminergic agonists
haloperidol, 995
lesions, ventral noradrenergic bundle, 619
α-methylparatyrosine, 995
noradrenergic-dopaminergic interaction, 619
pigeons, 995
piribedil, 995
rotational behavior, 619
scheduled responding, 995
tetrabenzine, 995
Dopaminergic system
ACTH, 31
amphetamine, 431
brain stimulation, 431
circling behavior, 431
dopamine agonists, 31
dopamine antagonists, 31
grooming, 31
lesions, hippocampus, 193
locomotor activity, 31
nucleus accumbens, 193
open field, 193
pimozide, 431
recovery of function, 193
substantia nigra, 431
Dose-dependent effects, 177
$ACTH_{4-9}$ analog
active avoidance
ORG-2766
passive avoidance
Dose response
analgesia, 757
food deprivation, 563
goldfish, 757
MIF-1, 757
morphine, 757
naloxone, 757
reward deprivation, 563
self-administration, 563
water deprivation, 563
Dose-response relationships, 1213
analgesia
Formalin test
morphine tolerance
tail-flick test
Drinking
acetylsalicylic acid, 73
adipsia, 249
alcohol preference, 763, 831, 861
ambulatory activity, 519
angiotensin, 741
anorexia, 249
anticonflict effects, 1
antipsychotics, 1049
aspartic acid, 1265
behavioral side-effects, 1225
benzodiazepines, 481
bethanechol, 727
blood pressure, arterial, 741
body weight, 1225
caffeine, 481
cancer chemotherapy, 1225
β-carbolines, 831
cellular dehydration, 73
clonidine, 519
clozapine, 1049
collateral behavior, 1049
concurrent schedule, 341
core temperature, 1265
crinia-angiotensin II, 741
2-deoxy-D-glucose, 955
eating, 249, 341, 955, 1049, 1265
endorphins, 1275
fixed-ratio, 341
food deprivation, 341
glucocorticoids, 1225
glucoprivation, 955
gonads, 1225
guanfacine, 519
haloperidol, 1049
hypertension, 519
hypodipsia, 481
hypothalamus, 249
hypovolemia, 73
ICV infusion, 831
indomethacin, 73
intravenous infusion, 763
isoproterenol, 1
methylphenidate, 1089
4-methylpyrazole, 763
milk intake, 1089, 1275
naloxone, 1287
naloxone methobromide, 1287
nociception, 1225

operant behavior, 1049
opiate agonists, 1275
opiate antagonists, 1275, 1287
opiate receptors, 1275
parasympathomimetic agents, 727
phencyclidine, 341
pigeons, 741
pituitary-adrenal axis, 1225
plasma angiotensin II, 73
prednisolone, 1225
primates, 1275
prostaglandin E, 73
rabbits, 1049
rats, 741
renin-angiotensin system, 727
rhesus monkeys, 341
route of administration, 1089
satiety, 341, 481
schedule-induced behavior, 1049
scheduled responding, 1049
self-administration, 341
squirrel monkeys, 1275
starvation, 249
thiothixene, 1049
TRH, 249
urine outflow, 1265
water deficits, 955
DRL schedule, 85
anticholinergics
atropine
benactyzine
rhesus monkey
schedule-controlled behavior
scopolamine
Drug
acetaldehyde, 807, 1103
acetylcholine, 1285
acetylsalicylic acid, 73, 305
adenosine, 749, 1285
alcohol, 831, 961, 1093
amitriptyline, 461, 645, 847, 1221
amphetamine, 5, 15, s43, 99, 255, 271, 375, 381, 431, 445, 547, 563, 613, 619, 671, 709, 1257, 1305
d-amphetamine, 25, 413, 539, 645, 1123
d,l-amphetamine, 1129
anisomycin, 187
Antabuse®, 1103
apomorphine, s1, 11, s21, 31, s43, 59, 375, 393, 619, 651, 671, 873, 967, 1015, 1115, 1233, 1251, 1281, 1305, 1309
arecoline, 703
N-methyl-D-aspartate, 715
atropine, 85, 851
atropine methyl bromide, 797
atropine methyl nitrate, 19, 863
atropine sulfate, 727
baclofen, 855, 1207
l-baclofen, 451
benactyzine, 85
benzodiazepine, 313
benztropine, 851
bethanecol, 727
bicuculline, 451, 709, 973
biochanin A, 405
bromocriptine, s1, 837
buspirone, s25, s37
butaclamol, 31
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417), 797
caffeine, 481, 613
calmodulin, 1257
captopril, 727
carbachol, 371
3-carbomethoxy-β-carboline, 457
1,2,3,4-tetrahydro-β-carboline, 831
1-methyl-1,2,3,4-tetrahydro-β-carboline, 831
CGS 8216, 457
chlordiazepoxide, 141, 645, 709, 921, 973, 1165
p-chloroamphetamine, 467
p-chlorophenylalanine, 597, 945, 1043
chlorpheniramine, 305
chlorpromazine, 385, 425, 645, 1061, 1309
cimetidine, 305
clonidine, 399, 519, 655, 1207
clozapine, 987, 1049
coca, 1087
cocaine, 563, 671, 823, 901, 1087, 1295
codeine, 1141
cycloheximide, 187
N-demethylchlordiazepoxide, 141
2-deoxy-D-glucose, 955
2-deoxyglucose, 1145
desipramine, 377, 435
desmethylimipramine, 847, 1281
dexamethasone, 305
dextrorphan, 1141
diazepam, 1, 59, 165, 359, 367, 457, 481, 645, 1055, 1171
digitoxin, 399
^{3}H-dihydroalprenolol, 159
[^{3}H]dihydromorphine, 699
5,7-dihydroxytryptamine, 973
diisopropyl phosphorofluoridate (DFP), 885, 1001
1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), 603
dimethyl sulfoxide, 305
diphenhydramine, 851
diprenorphine, 347, 1275
dipyridamole, 749
disulfiram, 1103
domperidone, 305
dopamine, 203
DSP-4, 1257
DU27716, 147
D-Ala^{2}-Met^{5}-enkephalinamide, 19
ergocornine, 837
ethanol, 111, 119, 125, 141, 233, 245, 323, 333, 529, 563, 569, 609, 629, 685, 763, 813, 927, 1037, 1073, 1097, 1103, 1239, 1313
ethanolamine-O-sulfate, 1145
ethylketocyclazocine, 1275
etonitazene, 563, 703
etorphine, 1275
fenfluramine, 99
fentanyl, 297
ferulic acid, 405
[^{3}H]flunitrazepam, 313
fluoxetine, 435
flupenthixol, 681
fluphenazine, 987
fluphenazine decanoate, 25
flurothyl, 91
GABA, 651, 703
γ-vinyl GABA, 99, 451
glutamic acid diethylester, 715
guanfacine, 519
haloperidol, 15, 31, 131, 263, 305, 393, 503, 613, 671, 681, 703, 851, 855, 951, 995, 1027, 1049, 1207, 1295, 1309
hashish, 209
heroin, 563
6-hydroxydopamine, 5, 77, 99, 1281
imipramine, 159, 461, 645, 847, 1119
indomethacin, 73, 1233
insulin, 1145
iprindole, 461, 1221
isoproterenol, 1, 727, 1257, 1285
kainic acid, 715
ketamine, 291
ketocyclazocine, 1141, 1275
levorphanol, 1141
lithium, 377, 435
lithium carbonate, 1317
lithium chloride, 695, 1317
lysergic acid diethylamide (LSD), 539, 589

LSD-25, 671
MD 790501, 1309
meperidine, 489
meprobamate, 645
metergoline, 99
methadone, 371, 489
methamphetamine, 425, 1251
methocarbamol, 1207
methyl atropine, 53
α-methylparatyrosine, 995
methylphenidate, 1089
4-methylpyrazole, 763, 1103
3-methyl-6-[3-trifluoromethylphenyl]-1,2,4-triazolo[4,3-b]pyridazine (CL 218,872), 709
N-methyl-1,6-dihydro-pyridine-2-carbaldoxime hydrochloride (proPAM), 1001
iso-butyl-methylxanthine, 655
methysergide, 393, 503, 877
metoclopramide, 31, 1207
mianserin, 461
midazolam, 481
morphine, 1141, 1161, 1175, 1213, 1275
morphine sulfate, 19, 107, 223, 229, 297, 389, 371, 419, 489, 495, 645, 671, 703, 715, 749, 757, 789, 897, 1019, 1181
muscimol, 451, 651, 973, 1165
naloxazone, 1175
naloxone, 19, 37, 119, 223, 297, 305, 347, 387, 655, 691, 749, 757, 789, 813, 897, 905, 1083, 1141, 1165, 1181, 1203, 1271, 1275, 1287, 1301
naloxone methobromide, 1287
naltrexone, 297, 691, 733, 921, 1019, 1271, 1275
nialamide, 1135
nicotine, 183, 579, 733, 915, 1077
nitroglycerine, 1285
nomifensine, 951
norepinephrine, 1257, 1285
ORG-2766, 177
oxazepam, 43
oxotremorine, 53
pargyline, 1135
pentazocine, 107, 489, 789
pentobarbital, 245, 353, 695, 797
pentylenetetrazol, 709, 1111
pethidine, 371
phencyclidine, 53, 291, 341, 353, 503, 539, 563, 1141
[^{3}H]phencyclidine, 699
phenobarbital, 645
phenyldiguanide, 19
phenylethylamine, 1291
phenylpiperazine, 147
physostigmine, 1119, 1295
picrotoxin, 359, 451, 651, 1165
pilocarpine, 425
pimozide, 31, 431, 613, 665, 769, 783, 841, 967, 987, 1245, 1305
piribedil, 995
polyethylene glycol, 921
prazosin, 1207
prednisolone, 1225
procaine, 1295
propranolol, 255, 399, 671, 727
N-propylapomorphine, s1
pyridine-2-aldoxime methyl iodide (PAM), 1001
[^{3}H]-quinuclidinyl benzilate, 159, 313
quipazine, 393
quisqualic acid, 715
R 18 503, 1155
reserpine, 283, 1203, 1257
Ro5-3663, 481
Ro 15-1788, 457
Rolipram, 677
saccharin, 1129
salsolinol, 813
scopolamine, 85, 425, 933, 1123
SKF 10,047, 539, 789
sodium barbitone, 909
sodium n-dipropylacetate, 451
sodium pentobarbital, 539
^{99m}Tc-sodium pertechnetate, 1199
[^{3}H]spiperone, 699
streptomycin, 363
strychnine, 709
sucrose, 333
sulpiride, 1257
sultopride, 1309
tetrabenzine, 995
Δ-tetrahydrocannabinol, 539, 671
tetrahydropapaveroline, 813
thioridazine, 1309
thiothixene, 1049
tofizopam, 367
tranylcypromane, 1135
trazodone, 1221
triamcinolone acetonide, 473
trifluoperazine, 1257
tripelennamine, 789
l-tryptophan, 877
tyramine, 1291
U-49,274A, 107
U-50,488, 107
valerian, 65
valproic acid, 49
Drug associations, 695
  conditioned drug effects
  hypothermia
  lithium chloride
  pentobarbital
Drug discrimination
  alcohol, 1093
  apomorphine, 393
  benzodiazepines, 709
  brain stimulation, 1093
  chlordiazepoxide, 709
  diazepam, 1171
  dopaminergic action, 393
  drug stimulus complex, 1171
  haloperidol, 393
  ketamine, 291
  methysergide, 393
  morphine, 789
  N-allyl-normetazocine (SKF10,047), 789
  naloxone, 789
  pentazocine, 789
  phencyclidine, 291
  quipazine, 393
  reward, 1093
  schedule-controlled behavior, 291
  serotonin, 393
  stereospecificity, 291
  triazolopyridazines, 709
  tripelennamine, 789
Drug effects, 1285
  cardiac tissue, transplant
  microvasculature
Drug experience effects, 43
  benzodiazepines
  Geller-Seifter conflict test
  individual variability
  oxazepam
  rate dependency
  tolerance
Drug interaction
  chlordiazepoxide, 141
  N-demethylchlordiazepoxide, 141
  drug discrimination, 789
  ethanol-induced sleep time, 141
  fixed-ratio, 353
  methyl atropine, 53
  morphine, 789
  motor performance, 53
  N-allyl normetazocine (SKF 10,047), 789

naloxone, 789
operant behavior, 353
oxotremorine, 53
pentazocine, 789
pentobarbital, 353
phencyclidine, 353
phencyclidine lethality, 53
phencyclidine metabolites, 53
pigeons, 353
repeated acquisition, 353
response chains, 353
tripelennamine, 789
Drug stimulus complex, 1171
diazepam
drug discrimination
Drugs of abuse
alcohol, 233
brain reward systems, 233, 239
opiates, 239
DSIP, 511
circadian rhythms
neurotransmitters
plasma proteins
DSIP analogs, 1187
age
blood-brain barrier
delta sleep-inducing peptide (DSIP)
radioimmunoassay
DU27716, 147
aggression inhibition
brain stimulation, electrical
hypothalamus
phenylpiperazines
Dysphoria, 107
corticosteroids
opiate analgesics
self-administration

Early development, 137
caffeine
jewel fish
spatial behavior
Eating
adipsia, 249
amphetamine, 99, 255
anorexia, 99, 249, 255, 539
antipsychotics, 1049
aspartic acid, 1265
cancer anorexia, 1043
catecholamines, 255
p-chlorophenylalanine, 1043
clozapine, 1049
collateral behavior, 1049
concurrent schedule, 341
core temperature, 1265
2-deoxy-D-glucose, 955
dopamine, 1043
drinking, 249, 341, 955, 1049, 1265
fenfluramine, 99
fixed-ratio, 341
food deprivation, 341
GABA, 99
glucoprivation, 955
hallucinogens, 539
haloperidol, 1049
6-hydroxydopamine, 99
5-hydroxyindoleacetic acid, 1043
hyperphagia, 539
hyperthermia, 1141
hypothalamus, 249
locomotor activity, 99
log survivor analysis, 255
metergoline, 99
microstructural analysis, 255
morphine, 1141
norepinephrine, 1043
operant behavior, 1049
opiate receptors, 1141
phencyclidine, 341
propranolol, 255
rabbits, 1049
rhesus monkeys, 341
satiety, 341
schedule-induced behavior, 1049
scheduled responding, 1049
self-administration, 341
serotonin, 1043
starvation, 249
thiothixene, 1049
TRH, 249
tryptophan, 1043
urine outflow, 1265
ventromedial hypothalamus, 1141
water deficits, 955
Eclampsia, 91
aldehyde dehydrogenase
aldehyde oxidase
flurothyl
pregnancy, mice
pyridoxal kinase
pyridoxamine phosphate oxidase
seizure susceptibility
Electroconvulsive shock, 375
amphetamine
apomorphine
dopamine autoreceptors
Electroshock, 377
aggression
desipramine
lithium
Emotionality
alcohol, 961
corticosterone, 1077
defecation, 961
genetic differences, 961
locomotor activity, 1077
open field, 961, 1077
prenatal nicotine, 1077
rearing, 1077
sex differences, 961, 1077
Endocrine effects, 529
adrenalectomy
corticosterone
estradiol
ethanol
hamsters
ovariectomy
Endogenous opiates, 1019
analgesia, stress-induced
inescapable shock
learned helplessness
morphine hyperreactivity
naltrexone
Endogenous opioid-like peptide, 1271
behavioral depression
bradycardia
hibernation "trigger"
hypophagia
hypothermia
opioid antagonists
plasma albumin fraction
rhesus monkey
Endorphins
abstinence syndrome, 389
chronic administration, 389
dependence, 389
drinking, 1275
milk intake, 1275
morphine, 389

naloxone, 389
opiates, 389
opiate agonists, 1275
opiate antagonists, 1275
opiate receptors, 1275
primates, 1275
squirrel monkeys, 1275
β-Endorphin
ACTH, 1203
behavioral effects, 703
cat, 1317
catalepsy, 703
corticotropin releasing factor (CRF), 1203
hypothermia, 1203
lithium, 1317
morphine, 703
α-MSH, 1203
naloxone, 1203
opiates, 703
opiate receptors, 1317
ptosis, 1203
psychomotor excitation, 1317
reserpine, 1203
sedation, 1203
temperature, 1203
Enkephalin analogs, 217
amygdala central nucleus
heart rate conditioning
opiate receptors
rabbits
Leu-Enkephalin, 1301
cardiovascular activity
dog
MIF-1
naloxone
Met-Enkephalin, 813
cortical neurons
ethanol
hippocampal pyramidal neurons
naloxone
opiates
salsolmiol
tetrahydroisoquinolines
tetrahydropaveroline
D-Ala^2-Met^5-Enkephalinamide, 19
cardiovascular reflex
morphine
motor activity
phenyldiguanide
pulmonary J-receptors
pulmonary opaite receptors
vagal afferents
Entorhinal cortex, 77
6-hydroxydopamine
lesions, A10
passive avoidance
septum
tree shrews
tyrosine hydroxylase
Environmental effects, 467
aggregation toxicity
catecholamines
p-chloroamphetamine
stress
Environmental enrichment, 313
aging mice
benzodiazepine
cholinergic receptors
passive avoidance
Environmental influences, 49
housing, group
housing, isolation
serotonin metabolism
valproic acid
Ergot drugs, 837
corticosterone
growth hormone
lactation
luteinizing hormone
prolactin
Escape performance, 263
haloperidol
inescapable shock
stress
Estradiol, 529
adrenalectomy
corticosterone
endocrine effects
ethanol
hamsters
ovariectomy
Estrogen, 1027
catalepsy
haloperidol
neuroleptics
Estrous cycle
brain indoleamines, 857
chronic ethanol, 629
development, 659
ethanol preference, 323
lactation, 323
malnutrition, postnatal, 659
malnutrition, prenatal, 659
ovarian function, 629
ovariectomy, 323, 857
paced coital stimulation, 857
pregnancy, 323, 629
reproductive state, female rat, 323
sexual behavior, 659
taste, 323
vaginal patency, 629
Ethanol
acetaldehyde, 1103
adenosine triphosphatase, 927
adrenalectomy, 529
age differences, 1037
albino rats, 1313
Antabuse®, 1103
anxiolytic agents, 645
behavior, 111
benzodiazepines, 645
blood alcohol levels, 111
blood pressure, 1103
cerebellum, 569
chlordiazepoxide, 1239
conflict test, 645
cortical neurons, 813
corticosterone, 529
disulfiram, 1103
endocrine effects, 529
Met-enkephalin, 813
estradiol, 529
fetal alcohol syndrome, animal model, 125
genetic differences, 1073
hamsters, 529
heart rate, 1103
hippocampal pyramidal neurons, 813
hypnotic effects, 569
inbred strains, mice, 569
intoxication, 1037
maternal behavior, female rat, 125
meprobamate, 645
4-methylpyrazole, 1103
naloxone, 813
opiates, 813
oral intubation, 111
ovariectomy, 529
phenobarbital, 645
photic evoked potentials, 1313

physical dependence, 1239
postnatal exposure, 927
pregnancy, 111, 125
prenatal exposure, 927
Purkinje neurons, 569
righting reflex, 569
salsolinol, 813
squirrel monkeys, 111
squirrel monkeys, male, 645
superior colliculus, 1313
tetrahydroisoquinolines, 813
tetrahydropapaveroline, 813
tolerance, 1073, 1239
visual cortex, 1313
withdrawal, 125, 1037, 1239
Ethanol dependence, 609
conditioned taste preference
withdrawal syndrome
Ethanol-induced sleep time, 141
chlordiazepoxide
N-demethylchlordiazepoxide
drug interactions
Ethanol preference, 323
estrous cycle
lactation
ovariectomy
pregnancy
reproductive state, female rat
taste
Ethanol reinforced responding, 333
concurrent schedules
sucrose
Ethanol sensitivity, 245
hypnosis
hypothermia
pentobarbital
pharmacogenetics
pharmacokinetics
Ethanol tolerance, 685
neurohypophyseal peptides
vasopressin
Ethanolamine-O-sulfate, 1145
2-deoxyglucose
GABA
glucoprivic feeding
insulin
Evoked potentials, 1061
neuroleptics
oral dyskinesia
substantia nigra
tardive dyskinesia
Extinction
baclofen, 1207
clonidine, 1207
dopamine, 769
haloperidol, 1207
intracranial self-stimulation, 1207
methocarbamol, 1207
metoclopramide, 1207
morphine analgesia, 229
neuroleptics, 769
nociception, 229
pimozide, 769
prazosin, 1207
reinforcement, 769
response decrement patterns, 1207
self-stimulation, 769
stress, 229
tolerance, 229
Exploratory behavior, 1165
ataxia
chlordiazepoxide
locomotor activity
muscimol
muscle relaxation
naloxone
picrotoxin

Fenfluramine, 99
amphetamine
anorexia
eating
GABA
6-hydroxydopamine
locomotor activity
metergoline
Ferulic acid, 405
biochanin A
dietary supplements
quail
sexual behavior, birds
Fetal alcohol syndrome, animal model, 125
ethanol
maternal behavior, female rat
pregnancy
withdrawal
Fixed-ratio
body temperature, 885
concurrent schedule, 341
diarrhea, 885
diisopropyl phosphorofluoridate, 885
drinking, 341
drug interactions, 353
eating, 341
food deprivation, 341
generalization, 885
locomotor activity, 885
operant behavior, 353
pentobarbital, 353
phencyclidine, 341, 353
pigeons, 353
repeated acquisition, 353
response chains, 353
rhesus monkeys, 341
satiety, 341
selective breeding, 885
self-administration, 341
Fluoxetine, 435
conditioned taste aversion
desipramine
lesions, dorsal noradrenergic bundle
lesions, raphe nuclei
lithium
pretreatment effect
Flupenthixol, 681
castration
haloperidol
luteinizing hormone
testosterone
Fluphenazine, 987
anhedonia paradigm refinements
clozapine
pimozide
Fluphenazine decanoate, 25
d-amphetamine
locomotor activity
sensitivity
serum prolactin
Flurothyl, 91
aldehyde dehydrogenase
aldehyde oxidase
eclampsia
pregnancy, mice
pyridoxal kinase
pyridoxamine phosphate oxidase
seizure susceptibility
Food deprivation
acetaldehyde, 807
body weight, 807

concurrent schedule, 341
dose response, 563
drinking, 341
eating, 341
fixed-ratio, 341
phencyclidine, 341
photoperiod, 807
reward deprivation, 563
rhesus monkeys, 341
satiety, 341
schedule-controlled responding, 807
self-administration, 341, 563
self-injection, 807
water deprivation, 563
Footshock
$ACTH_{1-24}$, 37
defensive fighting, 451
deoxyglucose uptake, 37
GABA, 451
$MSH/ACTH_{4-10}$, 37
naloxone, 37
Formalin test, 1213
analgesia
dose-response relationships
morphine tolerance
tail-flick test
Free recall, 165
acquisition deficits
cognition
diazepam
human studies
paired-associate learning
serial learning
serial position effects
Fucose, 203
dopamine
fucosyltransferase
GDB-fucose
glycoprotein synthesis
hippocampus
GDP-fucose, 203
dopamine
fucose
fucosyltransferase
glycoprotein synthesis
hippocampus
Fucosyltransferase, 203
dopamine
fucose
GDP-fucose
glycoprotein synthesis
hippocampus

GABA
amphetamine, 99
anorexia, 99
apomorphine, 651
benzodiazepines, 973
climbing behavior, 651
defensive fighting, 451
2-deoxyglucose, 1145
eating, 99
ethanolamine-O-sulfate, 1145
fenfluramine, 99
footshock, 451
glucoprivic feeding, 1145
6-hydroxydopamine, 99
5-hydroxytryptamine, 973
insulin, 1145
in vivo studies, 651
locomotor activity, 99, 973
metergoline, 99
muscimol, 651, 973
picrotoxin, 651
ventral tegmental nuclei of Gudden, 973
GABA receptors, 855
baclofen
catalepsy, haloperidol-induced
GABAergic system, 359
anxiolytics
conditioned defensive burying
diazepam
picrotoxin
Geller-Seifter conflict test, 43
benzodiazepines
drug experience effects
individual variability
oxazepam
rate dependency
tolerance
Generalization
amphetamine, 671
antagonism, 671
body temperature, 885
diarrhea, 885
diisopropyl phosphorofluoridate, 885
discriminative stimulus, 671
fixed-ratio responding, 885
locomotor activity, 885
pigeons, 671
selective breeding, 885
Genetic differences
alcohol, 961
defecation, 961
emotionality, 961
ethanol, 1073
open field reactivity, 961
sex differences, 961
tolerance, 1073
Genetically obese mice, 271
amphetamine
anorexia
brain catecholamine levels
hyperglycemia
hyperphagia
obesity
Gerbils
amphetamine, 1305
apomorphine, 1305
dopamine, 1305
MIF-1, 1083
naloxone, 1083
neurotransmitters, 1305
opiate antagonists, 1083
pimozide, 1305
social behavior, 1305
stereotypy, 1305
vascular stroke, 1083
Glucocorticoids, 1225
behavioral side-effects
body weight
cancer chemotherapy
drinking
gonads
nociception
pituitary-adrenal axis
prednisolone
Glucoprivation, 955
2-deoxy-D-glucose
drinking
eating
water deficits
Glucoprivic feeding, 1145
2-deoxyglucose
ethanolamine-O-sulfate
GABA
insulin
Glutamic acid diethylester, 715
kainic acid
N-methyl-D-aspartate

morphine
muscular rigidity
quisgualic acid
striatum
Glycoprotein synthesis
apomorphine, 11
consolidation, 11
dopamine, 203
fucose, 203
GDP-fucose, 203
fucosyltransferase, 203
hippocampus, 11, 203
Goldfish, 757
analgesia
dose-response
MIF-1
morphine
naloxone
Gonads, 1225
behavioral side-effects
body weight
cancer chemotherapy
drinking
glucocorticoids
nociception
pituitary-adrenal axis
prednisolone
Grooming, 31
ACTH
dopamine agonists
dopamine antagonists
dopaminergic system
locomotor activity
Growth hormone
cerebellum, 1067
corticosterone, 837, 1067
cyclic AMP, 1067
cyclic GMP, 1067
ergot drugs, 837
lactation, 837
luteinizing hormone, 837
pituitary, 1067
prolactin, 837, 1067
stress, 1067
Guanfacine, 519
ambulatory activity
clonidine
drinking
hypertension

H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
avoidance behavior
open-field
Hair cells, 363
aminoglycosides
ototoxicity
schooling behavior
streptomycin
tadpoles
Hallucinogens
amphetamines, 603
anorexia, 539
discriminative stimulus properties, 603
eating, 539
hyperphagia, 539
methoxyphenylisopropylamines, 603
phenylisopropylamines, 603
structure-activity relationships, 603
Haloperidol
active avoidance, 15
amphetamine, 15, 613
antipsychotics, 1049
apomorphine, 393
atropine, 851
avoidance suppression, 131
baclofen, 1207
benztropine, 851
caffeine, 613
catalepsy, 1027
castration, 681
clonidine, 1207
clozapine, 1049
cocaine, 1295
collateral behavior, 1049
diphenhydramine, 851
dopaminergic action, 393
dopaminergic agonists, 995
drinking, 1049
drug discrmination, 393
eating, 1049
escape performance, 263
estrogen, 1027
extinction, 1207
flupenthixol, 681
inescapable shock, 263
intracranial self-stimulation, 1207
luteinizing hormone, 681
β-[Tyr^8]melanotropin-(9–18), 15
methocarbamol, 1207
metoclopramide, 1207
α-methylparatyrosine, 995
methysergide, 393
neuroleptics, 1027
open field, 15
operant behavior, 1049
physostigmine, 1295
pigeons, 995
pimozide, 613
piribedil, 995
prazosin, 1207
procaine, 1295
quipazine, 393
rabbits, 1049
repeated administration, 131
response decrement patterns, 1207
schedule-induced behavior, 1049
scheduled responding, 995, 1049
self-administration, 1295
self-biting, 613
self-stimulation, 851
serotonin, 393
stress, 263
testosterone, 681
tetrabenzine, 995
thiothixene, 1049
Hamsters, 529
adrenalectomy
corticosterone
endocrine effects
estradiol
ethanol
ovariectomy
Hashish, 209
baboons
social behavior, male baboons
Head-poke response, 385
chlorpromazine
continuous avoidance
Heart rate
acetaldehyde, 1103
amitriptyline, 1221
Antabuse®, 1103
blood pressure, 1103, 1221
cardiovascular system, 1221
disulfiram, 1103
ethanol, 1103
iprindole, 1221
4-methylpyrazole, 1103
trazodone, 1221

Heart rate conditioning, 217
amygdala central nucleus
enkephalin analogs
opiate receptors
rabbits
Hibernation "trigger", 1271
behavioral depression
bradycardia
endogenous opioid-like peptide
hypophagia
hypothermia
opioid antagonists
plasma albumin fraction
rhesus monkey
Hippocampal pyramidal neurons, 813
cortical neurons
Met-enkephalin
ethanol
naloxone
opiates
salsolinol
tetrahydroisoquinolines
tetrahydropapaveroline
Hippocampus
adrenergics, 1257
apomorphine, 11
catecholamines, 1257
consolidation, 11
dopamine, 203
fucose, 203
GDP-fucose, 203
fucosyltransferase, 203
glycoprotein synthesis, 11, 203
in vitro studies, 1257
learning and memory, 1257
long-term potentiation, 1257
neuroleptics, 1257
Hormone
adrenaline, 555
1-desamino-8-D-arginine, 1123
corticosterone, 529, 837, 1067, 1077
estradiol, 529
estroten, 1027
growth hormone, 837, 1067
insulin, 305
luteinizing hormone (LH), 171, 681, 837
noradrenaline, 555
prolactin, 25, 837, 1067, 1149
prostaglandin, 1233
prostaglandin E, 73
testosterone, 681
Housing, group, 49
environmental influences
housing, isolation
serotonin metabolism
valproic acid
Housing, isolation, 49
environmental influences
housing, group
serotonin metabolism
valproic acid
Human studies
acquisition, 1055
acquisition deficits, 165
antemortem violence, 171
attention, 915
catecholamine excretion, 555
cigarette smoking, 155, 523, 915
cognition, 165
cortisol excretion, 555
diazepam, 165, 1055
free recall, 165
nicotine, 915
paired-associate learning, 165
postmortem plasma LH, 171
response consistency, 555
schedule-induced behavior, 523
scheduled responding, 1055
self-administration, 155, 523
serial learning, 165
serial position effects, 165
sex differences, 555
sleep latency, 65
sleep quality, 65
stress, 555
tobacco, 155
valerian, 65
visual evoked response, 915
Hunger, 863
atropine methyl nitrate
cholinergic blockade
diet palatability
sham feeding
6-Hydroxydopamine
amphetamine, 5, 99
anorexia, 99
apomorphine, 1233, 1281
appetitive conditioning, 1281
attentional deficit disorder, 5, 1281
circling behavior, 1233
developing rats, 5
dopamine depletion, 1281
eating, 99
entorhinal cortex, 77
fenfluramine, 99
GABA, 99
hyperactivity, 5, 1281
hyperkinesis, 5
indomethacin, 1233
lesions, A10, 77
locomotor activity, 99
metergoline, 99
passive avoidance, 77
prostaglandins, 1233
septum, 77
tree shrews, 77
tyrosine hydroxylase, 77
5-Hydroxyindoleacetic acid, 1043
cancer anorexia
p-chlorophenylalanine
dopamine
eating
norepinephrine
serotonin
tryptophan
5-Hydroxytryptamine, 973
benzodiazepines
GABA
locomotor activity
muscimol
ventral tegmental nuclei of Gudden
Hyperactivity
aggressive behavior, 503
amphetamine, 5
apomorphine, 1281
appetitive conditioning, 1281
attentional deficit disorders, 5, 1281
developing rats, 5
dopamine depletion, 1281
6-hydroxydopamine, 5, 1281
hyperkinesis, 5
phencyclidine, 503
Hyperglycemia, 271
amphetamine
anorexia
brain catecholamine levels
genetically obese mice
hyperphagia
obesity

Hyperkinesis, 5
amphetamine
attentional deficit disorder
developing rats
6-hydroxydopamine
hyperactivity
Hyperphagia
amphetamine, 271
anorexia, 271, 539
brain catecholamine levels, 271
eating, 539
genetically obese mice, 271
hallucinogens, 539
hyperglycemia, 271
obesity, 271
Hypertension, 519
ambulatory activity
clonidine
drinking
guanfacine
Hyperthermia, 1141
eating
morphine
opiate receptors
ventromedial hypothalamus
Hypnosis, 245
ethanol sensitivity
hypothermia
pentobarbital
pharmacogenetics
pharmacokinetics
Hypnotic effects, 569
cerebellum
ethanol
inbred strains, mice
Purkinje neurons
righting reflex
Hypodipsia, 481
benzodiazepines
caffeine
drinking
satiety
Hypokinesia, 283
corpus striatum
locomotion
nucleus accumbens
reserpine
Hypophagia, 1271
behavioral depression
bradycardia
endogenous opioid-like peptide
hibernation "trigger"
hypothermia
opiod antagonists
plasma albumin fraction
rhesus monkey
Hypothalamic-pituitary-adrenal axis, 721
norepinephrine
plasma corticosterone
prenatal stress
serotonin
Hypothalamus
adipsia, 249
aggression inhibition, 147
anorexia, 249
brain stimulation, electrical, 147
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417), 797
cholinergic mechanisms, 797
drinking, 249
DU27716, 147
eating, 249
pentobarbital antagonists, 797
phenylpiperazines, 147
sleep, 797
starvation, 249
TRH, 249, 797
Hypothermia
ACTH, 1203
behavioral depression, 1271
bradycardia, 1271
conditioned drug effects, 695
corticotropin releasing factor (CRF), 1203
drug associations, 695
endogenous opioid-like peptide, 1271
β-endorphin, 1203
ethanol sensitivity, 245
hibernation "trigger", 1271
hypnosis, 245
hypophagia, 1271
lithium chloride, 695
α-MSH, 1203
naloxone, 1203
opioid antagonists, 1271
pentobarbital, 245, 695
pharmacogenetics, 245
pharmacokinetics, 245
plasma albumin fraction, 1271
ptosis, 1203
reserpine, 1203
rhesus monkey, 1271
sedation, 1203
temperature, 1203
Hypothermia, ethanol-induced, 119
body temperature
naloxone
stress
Hypovolemia, 73
acetylsalicylic acid
cellular dehydration
drinking
indomethacin
plasma angiotensin Ii
prostaglandin E

ICV infusion, 831
alcohol preference
β-carbolines
drinking
Imipramine
cholinergic receptors, 159
depression, 159
memory, 1119
physostigmine, 119
REM sleep deprivation, 1119
serotonin, 159
suicide, 159
Implantable Nicotine Reservoir, 183
blood levels
body temperature
nicotine
sustained release
Inbred strains, mice, 569
cerebellum
ethanol
hypnotic effects
Purkinje neurons
righting reflex
Individual variability, 43
benzodiazepines
drug experience effect
Geller-Seifter conflict test
oxazepam
rate dependency
tolerance
Indomethacin
acetylsalicylic acid, 73
apomorphine, 1233
cellular dehydration, 73

circling behavior, 1233
drinking, 73
6-hydroxydopamine, 1233
hypovolemia, 73
plasma angiotensin II, 73
prostaglandin E, 73
prostaglandins, 1233
Inescapable shock
analgesia, stress-induced, 1019
endogenous opiates, 1019
escape performance, 263
haloperidol, 263
learned helplessness, 877, 1019
methysergide, 877
morphine hyperreactivity, 1019
naltrexone, 1019
serotonin, 877
stress, 263
tryptophan, 877
Ingestion method, 495
morphine intoxication
Insulin, 1145
2-deoxyglucose
ethanolamine-O-sulfate
GABA
glucoprivic feeding
Intoxication, 1037
age differences
ethanol
withdrawal
Intracerebral electrochemistry, 445
amphetamine
locomotion
nucleus accumbens
striatum
Intracranial self-stimulation
apomorphine, 1015
baclofen, 1207
clonidine, 1207
extinction, 1207
haloperidol, 1207
lesions, nucleus accumbens, 1015
lesions, 6-OHDA, 1015
methocarbamol, 1207
metoclopramide, 1207
prazosin, 1207
response decrement patterns, 1207
Intravenous infusion, 763
alcohol preference
drinking
4-methylpyrazole
In vitro studies, 1257
adrenergics
catecholamines
hippocampus
learning and memory
long-term potentiation
neuroleptics
In vivo studies, 651
apomorphine
climbing behavior
GABA
muscimol
picrotoxin
Iprindole, 1221
amitriptyline
blood pressure
cardiovascular system
heart rate
trazodone
Iron deficiency, s43
dopamine binding sites
Isolation housing, 691
aggressive behavior
opiate antagonists
social behavior
Isolation syndrome, 1291
aggressive behavior
phenylethylamine
stress
Isoproterenol, 1
anticonflict effects
drinking

Jewel fish, 137
caffeine
early development
spatial behavior

Kainic acid, 715
glutamic acid diethylester
N-methyl-D-aspartate
morphine
muscular rigidity
quisgualic acid
striatum
Ketamine, 291
drug discrimination
phencyclidine
schedule-controlled behavior
stereospecificity
Kindling, 1111
pentylenetetrazol
seizures
transfer
Kindling, amygdaloid, 461
acute administration
antidepressants
seizures
subacute administration

Lactation
alcohol preference, 1097
cohabitation, 1097
corticosterone, 837
ergot drugs, 837
estrous cycle, 323
ethanol preference, 323
growth hormone, 837
luteinizing hormone, 837
ovariectomy, 323
post-lactation, 1097
pregnancy, 323, 1097
prolactin, 837
reproductive state, female rat, 323
Lateral habenula, 841
^{14}C-2-deoxyglucose autoradiography
diagonal band of Broca
medial forebrain bundle
pimozide
reinforcement
self-stimulation
ventral tegmentum
Learned helplessness
analgesia, stress-induced, 1019
endogenous opiates, 1019
inescapable shock, 877, 1019
methysergide, 877
morphine hyperreactivity, 1019
naltrexone, 1019
serotonin, 877
tryptophan, 877
Learning, 909
appetitive tasks
aversive tasks
memory, long-term
sodium barbitone
Y-maze

Learning and memory, 1257
adrenergics
catecholamines
hippocampus
in vitro studies
long-term potentiation
neuroleptics
Lesions, A10, 77
entorhinal cortex
6-hydroxydopamine
passive avoidance
septum
tree shrews
tyrosine hydroxylase
Lesions, dorsal noradrenergic bundle
conditioned taste aversion, 435
desipramine, 435
fluoxetine, 435
lesions, raphe nuclei, 435
lithium, 435
neophobia, 639
plasma corticosterone, 639
pretreatment effect, 435
Lesions, hippocampus, 193
dopaminergic systems
nucleus accumbens
open field
recovery of function
Lesions, magnocellular forebrain, 933
acetylcholine release
avoidance behavior
scopolamine
Lesions, nucleus accumbens
apomorphine, 1015
intracranial self-stimulation, 1015
lesions, 6-OHDA, 579, 1015
nicotine, 579
schedule-induced behavior, 579
self-injection, 579
Lesions, 6-OHDA
apomorphine, 1015
cocaine, 901
intracranial self-stimulation, 1015
lesions, nucleus accumbens, 579, 1015
lesions, ventral tegmental area, 901
nicotine, 579
schedule-induced behavior, 579
self-administration, 901
self-injection, 579
Lesions, raphe nuclei, 435
conditioned taste aversion
desipramine
fluoxetine
lesions, dorsal noradrenergic bundle
lithium
pretreatment effect
Lesions, septum, 623
anxiety
aggression
neurotoxins
social interaction
Lesions, ventral noradrenergic bundle, 619
dopaminergic agonists
noradrenergic-dopaminergic interaction
rotational behavior
Lesions, ventral tegmental area, 901
cocaine
lesions, 6-OHDA
self-administration
Lethality, 1087
coca
cocaine
Lithium
aggression, 377
cats, 589, 1317
conditioned drug effects, 695
conditioned taste aversion, 435
cross-tolerance, 589
desipramine, 377, 435
drug associations, 695
electroshock, 377
β-endorphin, 1317
fluoxetine, 435
hypothermia, 695
lesions, dorsal noradrenergic bundle, 435
lesions, raphe nuclei, 435
LSD, 589
opiate receptors, 1317
pentobarbital, 695
pheromones, maternal, 1149
pretreatment effect, 435
prolactin, 1149
psychomotor excitation, 1317
synergism, 589
tactile stimulus, 589
Locomotion
amphetamine, 445
corpus striatum, 283
hypokinesia, 283
intracerebral electrochemistry, 445
nucleus accumbens, 283, 445
reserpine, 283
striatum, 445
Locomotor activity
ACTH, 31
amphetamine, 99, 547
d-amphetamine, 25
anorexia, 99
anxiety, 59
apomorphine, 59, 967
apomorphine antagonism, 1309
apomorphine stereotypy, 1115
ataxia, 1165
behavioral augmentation, 547
benzamides, 1309
benzodiazepines, 987
body temperature, 885
butyrophenones, 1309
chlordiazepoxide, 1165
conditioned suppression, 59
corticosterone, 1077
diarrhea, 885
diazepam, 59
diisopropyl phosphorofluoridate, 885
dopamine agonists, 31
dopamine antagonists, 31
dopamine receptors, 967
dopaminergic system, 31
eating, 99
emotionality, 1077
exploratory behavior, 1165
fenfluramine, 99
fixed-ratio responding, 885
fluphenazine decanoate, 25
GABA, 99, 987
generalization, 885
grooming, 31
6-hydroxydopamine, 99
5-hydroxytryptamine, 987
metergoline, 99
mice, male, 1181
muscimol, 987, 1165
muscle relaxation, 1165
naloxone, 1165
neuroleptics, 1309
open field, 1077
opiates, 1181
phenothiazines, 1309
picrotoxin, 1165
pimozide, 967

prenatal nicotine, 1077
rearing, 1077
repeated administration, 547
rhesus monkey, 1309
selective breeding, 885
sensitivity, 25
serum prolactin, 25
sex differences, 1077
sociosexual behavior, male mice, 1181
stereotypy, 547, 967
strain differences, 967, 1115
striatal dopamine receptors, 1115
sympathomimetics, 547
ventral tegmental nuclei of Gudden, 987
Log survivor analysis, 255
amphetamine
anorexia
catecholamines
eating
microstructural analysis
propranolol
Long-term potentiation, 1257
adrenergics
catecholamines
hippocampus
in vitro studies
learning and memory
neuroleptics
Luteinizing hormone
castration, 681
corticosterone, 837
ergot drugs, 837
flupenthixol, 681
growth hormone, 837
haloperidol, 681
lactation, 837
prolactin, 837
testosterone, 681
Lysergic acid diethylamide (LSD), 589
cats
cross-tolerance
limb-flicks
synergism
tactile stimulus

Malnutrition, postnatal, 659
development
estrous cycle
malnutrition, prenatal
sexual behavior
Malnutrition, prenatal, 659
development
estrous cycle
malnutrition, postnatal
sexual behavior
Matching-to-sample, 1123
d-amphetamine
1-desamino-8-D-arginine
memory, short-term
pigeons
scopolamine
vasopressin analogues
Maternal behavior, female rat, 125
ethanol
fetal alcohol syndrome, animal model
pregnancy
withdrawal
Medial forebrain bundle, 841
^{14}C-2-deoxyglucose autoradiography
diagonal band of Broca
lateral habenula
pimozide
reinforcement
self-stimulation
ventral tegmentum

Medial raphe nucleus, 597
p-chlorophenylalanine
β-[Tyr^9]melanotropin-(9–18), 15
self-stimulation
serotonin
time course analysis
active avoidance
amphetamine
haloperidol
open field
Memory
chicks, 893
cyclic AMP, 677
imipramine, 1119
passive avoidance, 677
physostigmine, 1119
L-prolyl-L-leucyl-glycineamide, 893
REM sleep deprivation, 1119
Rolipram, 677
Memory, long-term, 909
appetitive tasks
aversive tasks
learning
sodium barbitone
Y-maze
Memory, short term, 1123
d-amphetamine
1-desamino-8-D-arginine
matching-to-sample
pigeons
scopolamine
vasopressin analogues
Meprobamate, 645
anxiolytic agents
benzodiazepines
conflict test
ethanol
phenobarbital
squirrel monkeys, male
Metergoline, 99
amphetamine
anorexia
eating
fenfluramine
GABA
6-hydroxydopamine
locomotor activity
Methamphetamine, 1251
ambulatory activity
apomorphine
circadian variation
Methocarbamol, 1207
baclofen
clonidine
extinction
haloperidol
intracranial self-stimulation
metoclopramide
prazosin
response decrement patterns
Method
anhedonia paradigm refinements, 987
brain slice technique, 699
^{14}C-2-deoxyglucose autoradiography, 841
ICV technique, 651
ingestion method, 495
log survivor analysis, 255
microstructural analysis, 255
radioimmunoassay, 1187
TRS-80-based system for operant research, 583
Methoxyphenylisopropylamines, 603
amphetamines
discriminative stimulus properties
hallucinogens
phenylisopropylamines

structure-activity relationships
Methyl atropine, 53
drug interactions
motor performance
oxotremorine
phencyclidine lethality
phencyclidine metabolites
N-Methyl-1,6-dihydro-pyridine-2-carbaldoxime hydrochloride (proPAM), 1001
acetylcholinesterase reactivation
conditioned avoidance
DFP
oximes
PAM
thermoregulation
α-Methylparatyrosine, 995
dopaminergic agonists
haloperidol
pigeons
piribedil
scheduled responding
tetrabenzine
Methylphenidate, 1089
drinking
milk intake
route of administration
4-Methylpyrazole
acetaldehyde, 1103
alcohol preference, 763
Antabuse®, 1103
blood pressure, 1103
disulfiram, 1103
drinking, 763
ethanol, 1103
heart rate, 1103
intravenous infusion, 763
Methylxanthines, 655
clonidine
naloxone
withdrawal syndrome
Methysergide
apomorphine, 393
dopaminergic action, 393
drug discrimination, 393
haloperidol, 393
inescapable, 877
learned helplessness, 877
quipazine, 393
serotonin, 393, 877
tryptophan, 877
Metoclopramide, 1207
baclofen
clonidine
extinction
haloperidol
intracranial self-stimulation
methocarbamol
prazosin
response decrement patterns
Mice, male, 1181
locomotor activity
opiates
sociosexual behavior, male mice
Microstructural analysis, 255
amphetamine
anorexia
catecholamines
eating
log survivor analysis
propranolol
Microvasculature, 1285
cardiac tissue, transplant
drug effects
MIF-1
analgesia, 757
cardiovascular activity, 1301
dog, 1301
dose response, 757
Leu-enkephalin, 1301
gerbils, 1083
goldfish, 757
morphine, 757
naloxone, 757, 1083, 1301
opiate antagonists, 1083
vascular stroke, 1083
N-Tyr-MIF-1 binding sites, 1193
characterization
Tyr-MIF-1 receptors
Tyr-MIF-1 receptors, 1193
characterization
N-Tyr-MIF-1 binding sites
Milk intake
drinking, 1089, 1275
endorphins, 1275
methylphenidate, 1089
opiate agonists, 1275
opiate antagonists, 1275
opiate receptors, 1275
primates, 1275
route of administration, 1089
squirrel monkeys, 1275
Monoamine inhibitors, 1135
anorexia
catecholamine agonists
consummatory behavior
Morphine
abstinence syndrome, 389
acetylcholine, 419
adenosine, 749
N-allyl normetazocine (SKF 10,047), 789
analgesia, 419, 757, 1161, 1175
antagonism, 223
behavioral effects, 703
carbachol-induced fighting, 371
cardiovascular reflex, 19
catalepsy, 703
cats, 371
cerebral cortical prisms, 749
cholinergic neurons, 371
chronic administration, 389
cold water swims, 1175
collateral inhibition, 1175
corpus striatum, 419
dependence, 389
depressants, 371
dipyridamole, 749
discriminative stimulus properties, 223
dose-response, 757
drug discrimination, 789
drug interaction, 789
eating, 1141
endorphins, 389
β-endorphin, 703
D-Ala^2-Met^5-enkephalinamide, 19
glutamic acid diethylester, 715
goldfish, 757
hyperthermia, 1141
kainic acid, 715
N-methyl-D-aspartate, 715
MIF-1, 757
motor activity, 19
muscular rigidity, 715
mydriasis, 897
naloxazone, 1175
naloxone, 223, 389, 757, 789, 897
opiate receptors, 1141
opiates, 389, 703, 897
pentazocine, 789
phenyldiguanide, 19
pigeons, 223

prenatal exposure, 1161
pulmonary J-receptors, 19
pulmonary opiate receptors, 19
^{3}H-purines release, 749
quisqualic acid, 715
striatum, 715
tail flick, 1161
tolerance, 223
tripelennamine, 789
vagal afferents, 19
ventromedial hypothalamus, 1141
Morphine analgesia, 229
extinction
nociception
stress
tolerance
Morphine hyperreactivity, 1019
analgesia, stress-induced
endogenous opiates
inescapable shock
learned helplessness
naltrexone
Morphine-induced behavior, 297
cat
naloxone
opiate receptors
opioid peptides
septum
Morphine intoxication, 495
ingestion method
Morphine tolerance, 1213
analgesia
dose-response relationships
Formalin test
tail-flick test
Motor activity
cardiovascular reflex, 19
chronic administration, 489
dopamine receptors, 951
D-Ala-^{2}-Met^5-enkephalinamide, 19
morphine, 19
narcotics, 489
nomifensine, 951
phenyldiguanide, 19
pulmonary J-receptors, 19
pulmonary opiate receptors, 19
supersensitivity, 489
vagal afferents, 19
Motor performance, 53
drug interactions
methyl atropine
oxotremorine
phencyclidine lethality
phencyclidine metabolites
MSH/$ACTH_{4-10}$, 37
$ACTH_{1-24}$
deoxyglucose uptake
footshock
naloxone
α-MSH
ACTH, 1203
blood-brain barrier, 1199
central nervous system, 1199
corticotropin releasing factor (CRF), 1203
β-endorphin, 1203
hypothermia, 1203
naloxone, 1203
ptosis, 1203
reserpine, 1203
sedation, 1203
^{99m}Tc-sodium pertechnetate, 1199
temperature, 1203
Muricide, 847
antidepressants
serotonin
Muscimol
apomorphine, 651
ataxia, 1165
benzodiazepines, 973
chlordiazepoxide, 1165
climbing behavior, 651
exploratory behavior, 1165
GABA, 651, 973
5-hydroxytryptamine, 973
in vivo studies, 651
locomotor activity, 973, 1165
muscle relaxation, 1165
naloxone, 1165
picrotoxin, 651, 1165
ventral tegmental nuclei of Gudden, 973
Muscle relaxation, 1165
ataxia
chlordiazepoxide
exploratory behavior
locomotor activity
muscimol
naloxone
picrotoxin
Muscular rigidity, 715
glutamic acid diethylester
kainic acid
N-methyl-D-aspartate
morphine
quisqualic acid
striatum
Mydriasis, 897
morphine
naloxone
opiates

N-Allyl normetazocine (SKF 10,047), 789
drug discrimination
drug interaction
morphine
naloxone
pentazocine
tripelennamine
Naloxazone, 1175
analgesia
cold water swims
collateral inhibition
morphine
Naloxone
abstinence syndrome, 389
ACTH, 1203
$ACTH_{1-24}$, 37
analgesia, 757
antagonism, 223
ataxia, 1165
body temperature, 119
cardiovascular activity, 1301
cat, 297
chlordiazepoxide, 1165
chronic administration, 389
clonidine, 655
cortical neurons, 813
corticotropin releasing factor (CRF), 1203
deoxyglucose uptake, 37
dependence, 389
diprenorphine, 347
discriminative stimulus properties, 223
dog, 1301
dose-response, 757
drinking, 1287
drug discrimination, 789
drug interaction, 789
β-endorphin, 1203
endorphins, 389
Leu-enkephalin, 1301

Met-enkephalin, 813
ethanol, 813
exploratory behavior, 1165
footshock, 37
gerbils, 1083
goldfish, 757
hippocampal pyramidal neurons, 813
hypothermia, 1203
hypothermia, ethanol-induced, 119
locomotor activity, 1165
methylxanthines, 655
MIF-1, 757, 1083, 1301
morphine, 223, 389, 789, 897
morphine-induced behavior, 297
α-MSH, 1203
MSH/ACTH$^{4-10}$, 37
muscimol, 1165
muscle relaxation, 1165
mydriasis, 897
naloxone methobromide, 1287
narcotic antagonists, 347
N-allyl normetazocine (SKF 10,047), 789
opiate antagonists, 1083, 1287
opiate receptors, 297
opiates, 389, 813, 897
opioid peptides, 297
pentazocine, 789
picrotoxin, 1165
pigeons, 223
play fighting, 905
ptosis, 1203
reserpine, 1203
salsolinol, 813
sedation, 1203
septum, 297
social behavior, 905
spontaneous activity, 347
stress, 119
temperature, 1203
tetrahydroisoquinolines, 813
tetrahydropapaveroline, 813
tolerance, 223
tripelennamine, 789
vascular stroke, 1083
withdrawal syndrome, 655

Naloxone methobromide, 1287
drinking
naloxone
opiate antagonists
Naltrexone
analgesia, 733
analgesia, stress-induced, 1019
body temperature, 733
cardiac rates, 733
chlordiazepoxide, 921
dog, conscious, 733
endogenous opiates, 1019
inescapable shock, 1019
learned helplessness, 1019
morphine hyperreactivity, 1019
nicotine, 733
pupillary diameter, 733
respiratory rates, 733
thirst, hypervolemic, 921
thirst, osmotic, 921
Narcotic analgesics, 1155
neuroleptics
noradrenaline
R 18 503
serotonin
withdrawal
Narcotic antagonists, 347
diprenorphine
naloxone
spontaneous activity
Narcotics, 489
chronic administration
motor activity
supersensitivity
Nausea, 305
conditioned taste aversion
dexamethasone
radiation and behavior
Neonates, rats, 473
brain development
corticosteroids
radial maze
T-maze
triamocinolone acetonide
Neophobia, 639
lesions, dorsal noradrenergic bundle
plasma corticosterone
Neurohypophyseal peptides, 685
ethanol tolerance
vasopressin
Neuroleptics
adrenergics, 1257
apomorphine antagonism, 1309
avoidance, 1245
benzamides, 1309
butyrophenones, 1309
catalepsy, 1027
catecholamines, 1257
cue discrimination, 1245
dopamine, 769
estrogen, 1027
evoked potentials, 1061
extinction, 769
haloperidol, 1027
hippocampus, 1257
in vitro studies, 1257
learning and memory, 1257
locomotor activity, 1309
long-term potentiation, 1257
narcotic analgesics, 1155
noradrenaline, 1155
oral dyskinesia, 1061
phenothiazines, 1309
pimozide, 769, 1245
R 18 503, 1155
reinforcement, 769
response-choice discrimination, 1245
rhesus monkey, 1309
self-stimulation, 769
serotonin, 1155
substantia nigra, 1061
tardive dyskinesia, 1061
withdrawal, 1155
Neurotoxins, 623
aggression
anxiety
lesions, septum
social interaction
Neurotransmitters
amphetamine, 1305
apomorphine, 1305
circadian rhythms, 511
dopamine, 1305
DSIP, 511
gerbils, 1305
pimozide, 1305
plasma proteins, 511
social behavior, 1305
stereotypy, 1305
Nicotine
analgesia, 733
attention, 915
blood levels, 183

body temperature, 183, 733
cardiac rates, 733
cigarette smoking, 915
dog, conscious, 733
human studies, 915
Implantable Nicotine Reservoir, 183
lesions, 6-OHDA, 579
lesions, nucleus accumbens septum, 579
naltrexone, 733
pupillary diameter, 733
respiratory rates, 733
schedule-induced behavior, 579
self-injection, 579
sustained release, 183
visual evoked response, 915
Nociception
behavioral side-effects, 1225
body weight, 1225
cancer chemotherapy, 1225
drinking, 1225
extinction, 229
glucocorticoids, 1225
gonads, 1225
morphine analgesia, 229
pituitary-adrenal axis, 1225
prednisolone, 1225
stress, 229
tolerance, 229
Nomifensine, 951
dopamine receptors
motor activity
Noradrenaline, 1155
narcotic analgesics
neuroleptics
R 18 503
serotonin
withdrawal
Noradrenergic-dopaminergic interaction, 619
dopaminergic agonists
lesions, ventral noradrenergic bundle
rotational behavior
Norepinephrine
cancer anorexia, 1043
p-chlorophenylalanine, 1043
dopamine, 1043
eating, 1043
5-hydroxyindoleacetic acid, 1043
hypothalamic-pituitary-adrenal axis, 721
plasma corticosterone, 721
prenatal stress, 721
serotonin, 721, 1043
tryptophan, 1043
Nucleus accumbens
amphetamine, 445
corpus striatum, 283
dopaminergic systems, 193
hypokinesia, 283
intracerebral electrochemistry, 445
lesions, hippocampus, 193
locomotion, 283, 445
open field, 193
recovery of function, 193
reserpine, 283
striatum, 445

Obesity, 271
amphetamine
anorexia
brain catecholamine levels
genetically obsese mice
hyperglycemia
hyperphagia
Obesity, genetic, 939
amino acids
serotonin
tryptophan
Zucker rats
Open field
active avoidance, 15
amphetamine, 15
avoidance behavior, 633
corticosterone, 1077
dopaminergic systems, 193
emotionality, 1077
H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
haloperidol, 15
lesions, hippocampus, 193
locomotor activity, 1077
β-[Tyr^9]melanotropin-(9–18), 15
nucleus accumbens, 193
prenatal nicotine, 1077
rearing, 1077
recovery of function, 193
sex differences, 1077
Open field reactivity, 961
alcohol
defecation
emotionality
genetic differences
sex differences
Operant behavior
antipsychotics, 1049
clozapine, 1049
collateral, 1049
drinking, 1049
drug interactions, 353
eating, 1049
fixed-ratio, 353
haloperidol, 1049
pentobarbital, 353
phencyclidine, 353
pigeons, 353
rabbits, 1049
repeated acquisition, 353
response chains, 353
schedule-induced behavior, 1049
scheduled responding, 1049
thiothixene, 1049
Operant research, 583
BASIC
behavioral pharmacology
TRS-80 microcomputer
Opiate agonists, 1275
drinking
endorphins
milk intake
opiate antagonists
opiate receptors
primates
squirrel monkeys
Opiate analgesics, 107
corticosteroids
dysphoria
self-administration
Opiate antagonists
aggressive behavior, 691
drinking, 1275, 1287
endorphins, 1275
gerbils, 1083
isolation housing, 691
MIF-1, 1083
milk intake, 1275
naloxone, 1083, 1287
naloxone methobromide, 1287
opiate agonists, 1275
opiate receptors, 1275
primates, 1275
social behavior, 691
squirrel monkeys, 1275
vascular stroke, 1083

Opiate receptors
amygdala central nucleus, 217
brain slice technique, 699
cat, 297, 1317
chronic treatment, 699
dopamine receptors, 699
drinking, 1275
eating, 1141
endorphins, 1275
β-endorphin, 1317
enkephalin analogs, 217
heart rate conditioning, 217
hyperthermia, 1141
lithium, 1317
milk intake, 1275
morphine, 1141
morphine-induced behavior, 297
naloxone, 297
opiate agonists, 1275
opiate antagonists, 1275
opioid peptides, 297
phencyclidine receptors, 699
primates, 1275
psychomotor excitation, 1317
rabbits, 217
septum, 297
squirrel monkeys, 1275
ventromedial hypothalamus, 1141
Opiates
abstinence syndrome, 389
behavioral effects, 703
brain reward systems, 239
catalepsy, 703
chronic administration, 389
cortical neurons, 813
dependence, 389
drugs of abuse, 239
endorphins, 389
β-endorphin, 703
Met-enkephalin, 813
ethanol, 813
hippocampal pyramidal neurons, 813
locomotor activity, 1181
mice, male, 1181
morphine, 389, 703, 897
mydriasis, 897
naloxone, 389, 813, 897
salsolinol, 813
sociosexual behavior, male mice, 1181
tetrahydroisoquinolines, 813
tetrahydropapaveroline, 813
Opioid antagonists, 1271
behavioral depression
bradycardia
endogenous opioid-like peptide
hibernation "trigger"
hypophagia
hypothermia
plasma albumin fraction
rhesus monkey
Opioid peptides, 297
cat
morphine-induced behavior
naloxone
opiate receptors
septum
Oral dyskinesia, 1061
evoked potentials
neuroleptics
substantia nigra
tardive dyskinesia
Oral intubation, 111
behavior
blood alcohol levels
ethanol
pregnancy
squirrel monkeys
ORG-2766, 177
$ACTH_{4-9}$ analog
active avoidance
dose-dependent effects
passive avoidance
Ototoxicity, 363
aminoglycosides
hair cells
schooling behavior
streptomycin
tadpoles
Ovarian function, 629
chronic ethanol
estrous cycle, female rats
pregnant rats
vaginal patency
Ovariectomized rats, 857
brain indoleamines
estrous cycle
paced coital stimulation
Ovariectomy
adrenalectomy, 529
corticosterone, 529
endocrine effects, 529
estradiol, 529
estrous cycle, 323
ethanol, 529
ethanol preference, 323
hamsters, 529
lactation, 323
pregnancy, 323
reproductive state, female rat, 323
taste, 323
Oxazepam, 43
benzodiazepines
drug experience effects
Geller-Seifter conflict test
individual variability
rate dependency
tolerance
Oximes, 1001
acetylcholinesterase reactivation
conditioned avoidance
DFP
PAM
proPAM
thermoregulation
Oxotremorine, 53
drug interactions
methyl atropine
motor performance
phencyclidine lethality
phencyclidine metabolites

Paced coital stimulation, 857
brain indoleamines
estrous cycle
ovariectomized rats
Paired-associate learning, 165
acquisition deficits
cognition
diazepam
free recall
human studies
serial learning
serial position effects
Parasympathomimetic agents, 727
bethanechol
drinking
renin-angiotensin system
Passive avoidance
$ACTH_{4-9}$ analog, 177

active avoidance, 177
aging mice, 313
benzodiazepine, 313
cholinergic receptors, 313
cyclic AMP, 677
dose-dependent effects, 177
entorhinal cortex, 77
environmental enrichment, 313
6-hydroxydopamine, 77
lesions, A10, 77
memory, 677
ORG-2766, 177
Rolipram, 677
septum, 77
tree shrews, 77
tyrosine hydroxylase, 77
Pentazocine, 789
drug discrimination
drug interaction
morphine
N-allyl normetazocine (SKF 10,047)
naloxone
tripelennamine
Pentobarbital
conditioned drug effects, 695
drug associations, 695
drug interactions, 353
ethanol sensitivity, 245
fixed-ratio, 353
hypnosis, 245
hypothermia, 245, 695
lithium chloride, 695
operant behavior, 353
pharmacogenetics, 245
pharmacokinetics, 245
phencyclidine, 353
pigeons, 353
repeated acquisition, 353
response chains, 353
Pentobarbital antagonists, 797
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417)
cholinergic mechanisms
hypothalamus
sleep
TRH
Pentylenetetrazol, 1111
kindling
seizures
transfer
Peptide
ACTH, 31, 1203
$ACTH_{1-24}$, 37
angiotensin I, 1285
angiotensin II, 73, 741, 1285
corticotropin releasing factor (CRF), 1203
crinia-angiotensin II, 741
DSIP, 511, 1009, 1187
β-endorphin, 297, 703, 1203, 1317
Leu-enkephalih, 1301
D-Ala^2-D-Leu^5-enkephalin, 217
Met-enkephalin, 297, 813
H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH, 633
D-Ala^2-Met^5-enkephalinamide, 217
β-[Tyr^0]melanotropin-(9–18), 15
MIF-1, 757, 1083, 1301, 1193
N-Tyr-MIF-1, 1193
MSH, 893
α-MSH, 1199, 1203
$MSH/ACTH_{4-10}$, 37
oxytocin, 893
L-prolyl-L-leucyl-glycineamide, 893
thyrotropin-releasing hormone (TRH), 249, 797
vasopressin, 685
Pharmacogenetics, 245
ethanol sensitivity
hypnosis
hypothermia
pentobarbital
pharmacokinetics
Pharmacokinetics, 245
ethanol sensitivity
hypnosis
hypothermia
pentobarbital
pharmacogenetics
Pharmacotherapy, s25
antianxiety drugs
buspirone
dopamine
Phencyclidine
aggressive behavior, 503
concurrent schedule, 341
drinking, 341
drug discrimination, 291
drug interactions, 353
eating, 341
fixed-ratio, 341, 353
food deprivation, 341
hyperactivity, 503
ketamine, 291
operant behavior, 353
pentobarbital, 353
pigeons, 353
repeated acquisition, 353
response chains, 353
rhesus monkeys, 341
satiety, 341
schedule-controlled behavior, 291
self-administration, 341
stereospecificity, 291
Phencyclidine lethality, 53
drug interactions
methyl atropine
motor performance
oxotremorine
phencyclidine metabolites
Phencyclidine metabolites, 53
drug interactions
methyl atropine
motor performance
oxotremorine
phencyclidine lethality
Phencyclidine receptors, 699
brain slice technique
chronic treatment
dopamine receptors
opiate receptors
Phenobarbital, 645
anxiolytic agents
benzodiazepines
conflict test
ethanol
meprobamate
squirrel monkeys, male
Phenothiazines, 1309
apomorphine antagonism
benzamides
butyrophenones
locomotor activity
neuroleptics
rhesus monkey
Phenyldiguanide, 19
cardiovascular reflex
D-Ala^2-Met^5-enkephalinamide
morphine
motor activity
pulmonary J-receptors
pulmonary opiate receptors

vagal afferents
Phenylethylamine, 1291
aggressive behavior
isolation syndrome
stress
tyramine
Phenylisopropylamines, 603
amphetamines
discriminative stimulus properties
hallucinogens
methoxyphenylisopropylamines
structure-activity relationships
Phenylpiperazines, 147
aggression inhibition
brain stimulation, electrical
DU27716
hypothalamus
Pheromones, maternal, 1149
liver membranes
prolactin
Photic evoked potentials, 1313
albino rats
ethyl alcohol
superior colliculus
visual cortex
Photoperiod, 807
acetaldehyde
body weight
food deprivation
schedule-controlled responding
self-injection
Physical dependence, 1239
chlordiazepoxide
ethanol
tolerance
withdrawal
Physostigmine
cocaine, 1295
haloperidol, 1295
imipramine, 1119
memory, 1119
procaine, 1295
REM sleep deprivation, 1119
self-administration, 1295
Picrotoxin
anxiolytics, 359
apomoprhine, 651
ataxia, 1165
chlordiazepoxide, 1165
climbing behavior, 651
conditioned defensive burying, 359
diazepam, 359
exploratory behavior, 1165
GABA, 651
GABAergic system, 359
in vivo studies, 651
locomotor activity, 1165
muscimol, 651, 1165
muscle relaxation, 1165
naloxone, 1165
Pigeons
amphetamine, 671
d-amphetamine, 1123
angiotensin, 741
antagonism, 223, 671
blood pressure, arterial, 741
crinia-angiotensin II, 741
1-desamino-8-D-arginine, 1123
discriminative stimulus, 223, 671
dopaminergic agonists, 995
drinking, 741
drug interactions, 353
fixed-ratio, 353
generalization, 671
haloperidol, 995
matching-to-sample, 1123
memory, short-term, 1123
α-methylparatyrosine, 995
morphine, 223
naloxone, 223
operant behavior, 353
pentobarbital, 353
phencyclidine, 353
piribedil, 995
rats, 741
repeated acquisition, 353
response chains, 353
scheduled responding, 995
scopolamine, 1123
tetrabenzine, 995
tolerance, 223
vasopressin analogues, 1123
Pimozide
amphetamine, 431, 613, 1305
anhedonia paradigm refinements, 987
apomorphine, 967, 1305
avoidance, 1245
brain stimulation, 431
caffeine, 613
circling behavior, 431
clozapine, 987
cue discrimination, 1245
^{14}C-2-deoxyglucose autoradiography, 841
diagonal band of Broca, 841
dopamine, 769, 1305
dopamine receptors, 967
dopaminergic system, 431
extinction, 769
fluphenazine, 987
gerbils, 1305
haloperidol, 613
lateral habenula, 841
locomotor activity, 967
medial forebrain bundle, 841
neuroleptic treatment, 1245
neuroleptics, 769
neurotransmitters, 1305
place preference, 665
priming, 783
reinforcement, 769, 783, 841
response-choice discrimination, 1245
secondary reinforcement, 665
self-biting, 613
self-stimulation, 769, 783, 841
sign tracking, 665
social behavior, 1305
stereotypy, 967, 1305
strain differences, 967
substantia nigra, 431
ventral tegmentum, 841
Piribedil, 995
dopaminergic agonists
haloperidol
α-methylparatyrosine
pigeons
scheduled responding
tetrabenzine
Pituitary, 1067
cerebellum
corticosterone
cyclic AMP
cyclic GMP
growth hormone
prolactin
stress
Pituitary-adrenal axis, 1225
behavioral side-effects
body weight
cancer chemotherapy
drinking

glucocorticoids
gonads
nociception
prednisolone
Place preference, 665
pimozide
secondary reinforcement
sign tracking
Plasma albumin fraction, 1271
behavioral depression
bradycardia
endogenous opioid-like peptide
hibernation "trigger"
hypophagia
hypothermia
opioid antagonists
rhesus monkey
Plasma angiotensin II, 73
acetylsalicylic acid
cellular dehydration
drinking
hypovolemia
indomethacin
prostaglandin E
Plasma corticosterone
hypothalamic-pituitary-adrenal axis, 721
lesions, dorsal noradrenergic bundle, 639
neophobia, 639
norepinephrine, 721
prenatal stress, 721
serotonin, 721
Plasma proteins, 511
circadian rhythms
DSIP
neurotransmitters
Play fighting, 905
naloxone
social behavior
Post-lactation, 1097
alcohol preference
cohabitation
lactation
pregnancy
Postmortem plasma LH, 171
antemortem violence
human studies
Postnatal exposure, 927
adenosine triphosphatase
ethanol
prenatal exposure
Prazosin, 1207
baclofen
clonidine
extinction
haloperidol
intracranial self-stimulation
methocarbamol
metoclopramide
response decrement patterns
Prednisolone, 1225
behavioral side-effects
body weight
cancer chemotherapy
drinking
glucocorticoids
gonads
nociception
pituitary-adrenal axis
Pregnancy
alcohol preference, 1097
behavior, 111
blood alcohol levels, 111
cohabitation, 1097
estrous cycle, 323
ethanol, 111, 125
ethanol preference, 323
fetal alcohol syndrome, animal model, 125
lactation, 323, 1097
maternal behavior, female rat, 125
oral intubation, 111
ovariectomy, 323
post-lactation, 1097
reproductive state, female rat, 323
squirrel monkeys, 111
taste, 323
withdrawal, 125
Pregnancy, mice, 91
aldehyde dehydrogenase
aldehyde oxidase
eclampsia
flurothyl
pyridoxal kinase
pyridoxamine phosphate oxidase
seizure susceptibility
Pregnant rats, 629
chronic ethanol
estrous cycle, female rats
ovarian function
vaginal patency
Prenatal exposure
adenosine triphosphatase, 927
analgesia, 1161
ethanol, 927
morphine, 1161
postnatal exposure, 927
tail flick, 1161
Prenatal nicotine, 1077
corticosterone
emotionality
locomotor activity
open field
rearing
sex differences
Prenatal stress, 721
hypothalamic-pituitary-adrenal axis
norepinephrine
plasma corticosterone
serotonin
Pressing responses, 945
aggression, shock-induced
p-chlorophenylalanine
serotonin
Pretreatment effect, 435
conditioned taste aversion
desipramine
fluoxetine
lesions, dorsal noradrenergic bundle
lesions, raphe nuclei
lithium
Primates
baboons, 823
cocaine, 823
drinking, 1275
endorphins, 1275
milk intake, 1275
opiate agonists, 1275
opiate antagonists, 1275
opiate receptors, 1275
self-administration, 823
squirrel monkeys, 1275
tether restraint for catheterization, 823
Priming, 783
pimozide
reinforcement
self-stimulation
Procaine, 1295
cocaine
haloperidol
physostigmine
self-administration

Prolactin
cerebellum, 1067
corticosterone, 837, 1067
cyclic AMP, 1067
cyclic GMP, 1067
ergot drugs, 837
growth hormone, 837, 1067
lactation, 837
liver membranes, 1149
luteinizing hormone, 837
pheromones, maternal, 1149
pituitary, 1067
stress, 1067
L-Prolyl-L-leucyl-glycineamide, 893
chicks
memory
Propranolol
amphetamine, 255
anorexia, 255
behavioral toxicity, 399
cardioglycosides, 399
catecholamines, 255
clonidine, 399
digitoxin, 399
eating, 255
log survivor analysis, 255
microstructural analysis, 255
Prostaglandins, 1233
apomorphine
circling behavior
6-hydroxydopamine
indomethacin
Prostaglandin E, 73
acetylsalicylic acid
cellular dehydration
drinking
hypovolemia
indomethacin
plasma angiotensin II
Protein binding, 1009
blood-brain barrier
cerebrospinal fluid
column chromatography
dogs
DSIP
Protein synthesis inhibitors, 187
amnesia
anisomycin
catecholamine biochemistry
cycloheximide
Psychomotor excitation, 1317
cats
β-endorphin
lithium
opiate receptors
Ptosis, 1203
ACTH
corticotropin releasing factor (CRF)
β-endorphin
hypothermia
α-MSH
naloxone
reserpine
sedation
temperature
Pulmonary J-receptors, 19
cardiovascular reflex
D-Ala^2-Met^5-enkephalinamide
morphine
motor activity
phenyldiguanide
pulmonary opiate receptors
vagal afferents
Pulmonary opiate receptors, 19
cardiovascular reflex
D-Ala^2-Met^5-enkephalinamide
morphine
motor activity
phenyldiguanide
pulmonary J-receptors
vagal afferents
Pupillary diameter, 733
analgesia
body temperature
cardiac rates
dog, conscious
naltrexone
nicotine
respiratory rates
^{3}H-Purines release, 749
adenosine
cerebral cortical prisms
dipyridamole
morphine
Purkinje neurons, 569
cerebellum
ethanol
hypnotic effects
inbred strains, mice
righting reflex
Pyridine-2-aldoxime methyl iodide (PAM), 1001
acetylcholinesterase reactivation
conditioned avoidance
DFP
oximes
proPAM
thermoregulation
Pyridoxal kinease, 91
aldehyde dehydrogenase
aldehyde oxidase
eclampsia
flurothyl
pregnancy, mice
pyridoxamine phosphate oxidase
seizure susceptibility
Pyridoxamine phosphate oxidase, 91
aldehyde dehydrogenase
aldehyde oxidase
eclampsia
flurothyl
pregnancy, mice
pyridoxal kinase
seizure susceptibility

Quail, 405
biochanin A
dietary supplements
ferulic acid
sexual behavior, birds
Quantitative behavioral analysis, 873
apomorphine
stereotyped behavior
Quipazine, 393
apomorphine
dopaminergic action
drug discrimination
haloperidol
methysergide
serotonin
Quisqualic acid, 715
glutamic acid diethylester
kainic acid
N-methyl-D-aspartate
morphine
muscular rigidity
striatum

R 18 503 (α-(p-chlorophenyl)-β,β-dimethylimidazole-l-ethanol), 1155

narcotic analgesics
neuroleptics
noradrenaline
serotonin
withdrawal
Rabbits
amygdala central nucleus, 217
antipsychotics, 1049
clozapine, 1049
collateral behavior, 1049
drinking, 1049
eating, 1049
enkephalin analogs, 217
haloperidol, 1049
heart rate conditioning, 217
operant behavior, 1049
opiate receptors, 217
schedule-induced behavior, 1049
scheduled responding, 1049
thiothixene, 1049
Radial maze, 473
brain development
corticosteroids
neonates, rats
T-maze
triamocinolone acetonide
Radiation and behavior, 305
conditioned taste aversion
dexamethasone
nausea
Radioimmunoassay, 1187
age
blood-brain barrier
delta sleep-inducing peptide (DSIP)
DSIP analogs
Rate dependency, 43
benzodiazepines
drug experience effects
Geller-Seifter conflict test
individual variability
oxazepam
tolerance
Rats, 741
angiotensin
blood pressure, arterial
crinia-angiotensin II
drinking
pigeons
Rearing, 1077
corticosterone
emotionality
locomotor activity
open field
prenatal nicotine
sex differences
Recovery of function, 193
dopaminergic systems
lesions, hippocampus
nucleus accumbens
open field
Reinforcement
^{14}C-2-deoxyglucose autoradiography, 841
diagonal band of Broca, 841
dopamine, 769
extinction, 769
lateral habenula, 841
medial forebrain bundle, 841
neuroleptics, 769
pimozide, 769, 783, 841
priming, 783
self-stimulation, 769, 783, 841
ventral tegmentum, 841
REM sleep deprivation, 1119
imipramine
memory
physostigmine
Renin-angiotensin system, 727
bethanechol
drinking
parasympathomimetic agents
Repeated acquisition, 353
drug interactions
fixed-ratio
operant behavior
pentobarbital
phencyclidine
pigeons
response chains
Repeated administration
amphetamine, 547
avoidance suppression, 131
behavioral augmentation, 547
haloperidol, 131
locomotor activity, 547
stereotypy, 547
sympathomimetics, 547
Reproductive state, female rat, 323
estrous cycle
ethanol preference
lactation
ovariectomy
pregnancy
taste
Reserpine
ACTH, 1203
corpus striatum, 283
corticotropin releasing factor (CRF), 1203
β-endorphin, 1203
hypokinesia, 283
hypothermia, 1203
locomotion, 283
α-MSH, 1203
naloxone, 1203
nucleus accumbens, 283
ptosis, 1203
sedation, 1203
temperature, 1203
Respiratory rates, 733
analgesia
body temperature
cardiac rates
dog, conscious
naltrexone
nicotine
pupillary diameter
Response chains, 353
drug interactions
fixed-ratio
operant behavior
pentobarbital
phencyclidine
pigeons
repeated acquisition
Response-choice discrmination, 1245
avoidance
cue discrmination
neuroleptic treatment
pimozide
Response consistency, 555
catecholamine excretion
cortisol excretion
human studies
sex differences
stress
Response decrement patterns, 1207
baclofen
clonidine
extinction
haloperidol
intracranial self-stimulation

methocarbamol
metoclopramide
prazosin
Reward, 1093
alcohol
brain stimulation
drug discrimination
Reward deprivation, 563
dose response
food deprivation
self-administration
water deprivation
Rhesus monkey
anticholinergics, 85
apomorphine antagonism, 1309
atropine, 85
behavioral depression, 1271
benactyzine, 85
benzamides, 1309
bradycardia, 1271
butyrophenones, 1309
concurrent schedule, 341
drinking, 341
DRL schedule, 85
eating, 341
endogenous opioid-like peptide, 1271
fixed-ratio, 341
food deprivation, 341
hibernation "trigger", 1271
hypophagia, 1271
hypothermia, 1271
locomotor activity, 1309
neuroleptics, 1309
opioid antagonists, 1271
phencyclidine, 341
phenothiazines, 1309
plasma albumin fraction, 1271
satiety, 341
schedule-controlled behavior, 85
scopolamine, 85
self-administration, 341
Righting reflex, 569
cerebellum
ethanol
hypnotic effects
inbred strains, mice
Purkinje neurons
RO 15-1788, 457
benzodiazepine antagonists
3-carbomethoxy-β-carboline
CGS 8216
diazepam
seizures
Rolipram, 677
cyclic AMP
memory
passive avoidance
Rotational behavior, 619
dopaminergic agonists
lesions, ventral noradrenergic bundle
noradrenergic-dopaminergic interaction
Route of administration
amphetamine, 1129
conditioned taste aversion, 1129
drinking, 1089
methylphenidate, 1089
milk intake, 1089
saccharin, 1129

Saccharin, 1129
amphetamine
conditioned taste aversion
route of administration
Salsolinol, 813
cortical neurons
Met-enkephalin
ethanol
hippocampal pyramidal neurons
naloxone
opiates
tetrahydroisoquinolines
tetrahydropapaveroline
Satiety
benzodiazepines, 481
caffeine, 481
concurrent schedule, 341
drinking, 341, 481
eating, 341
fixed-ratio, 341
food deprivation, 341
hypodipsia, 481
phencyclidine, 341
rhesus monkeys, 341
self-administration, 341
Schedule-controlled responding
acetaldehyde, 807
anticholinergics, 85
atropine, 85
benactyzine, 85
body weight, 807
DRL schedule, 85
drug discrimination, 291
food deprivation, 807
ketamine, 291
phencyclidine, 291
photoperiod, 807
rhesus monkey, 85
scopolamine, 85
self-injection, 807
stereospecificity, 291
Schedule-induced behavior
antipsychotics, 1049
cigarette smoking, 523
clozapine, 1049
collateral behavior, 1049
drinking, 1049
eating, 1049
haloperidol, 1049
human studies, 523
lesions, nucleus accumbens septum, 579
lesions, 6-OHDA, 579
nicotine, 579
operant behavior, 1049
rabbits, 1049
scheduled responding, 1049
self-administration, 523
self-injection, 579
thiothixene, 1049
Scheduled responding
acquisition, 1055
antipsychotics, 1049
clozapine, 1049
collateral behavior, 1049
diazepam, 1055
dopaminergic agonists, 995
drinking, 1049
eating, 1049
haloperidol, 995, 1049
human studies, 1055
α-methylparatyrosine, 995
operant behavior, 1049
pigeons, 995
piribedil, 995
rabbits, 1049
schedule-induced behavior, 1049
tetrabenzine, 995
thiothixene, 1049
Schizophenia, etiology, 413
acoustic startle

d-amphetamine
sensitization
stress
Schooling behavior, 363
aminoglycosides
hair cells
ototoxicity
streptomycin
tadpoles
Scopolamine
acetylcholine release, 933
d-amphetamine, 1123
anticholinergics, 85
atropine, 85
avoidance behavior, 933
benactyzine, 85
1-desamino-8-D-arginine, 1123
DRL schedule, 85
lesions, magnocellular forebrain nuclei, 933
matching-to-sample, 1123
memory, short-term, 1123
pigeons, 1123
rhesus monkey, 85
schedule-controlled behavior, 85
vasopressin analogues, 1123
Secondary reinforcement, 665
pimozide
place preference
sign tracking
Sedation, 1203
ACTH
corticotropin releasing factor (CRF)
β-endorphin
hypothermia
α-MSH
naloxone
ptosis
reserpine
temperature
Seizures
acute administration, 461
antidepressants, 461
benzodiazepine antagonists, 457
3-carbomethoxy-β-carboline, 457
CGS 8216, 457
diazepam, 457
kindling, 1111
kindling, amygdaloid, 461
pentylenetetrazol, 1111
RO 15-1788, 457
subacute administration, 461
transfer, 1111
Seizure susceptibility, 91
aldehyde dehydrogenase
aldehyde oxidase
eclampsia
flurothyl
pregnancy, mice
pyridoxal kinase
pyridoxamine phosphate oxidase
Selective breeding, 885
body temperature
diarrhea
diisopropyl phosphorofluoridate
fixed-ratio responding
generalization
locomotor activity
Self-administration
baboons, 823
cigarette smoking, 155, 523
cocaine, 823, 901, 1295
concurrent schedule, 341
corticosteroids, 107
dose response, 563
drinking, 341
dysphoria, 107
eating, 341
fixed-ratio, 341
food deprivation, 341, 563
haloperidol, 1295
human studies, 155, 523
lesions, 6-OHDA, 901
lesions, ventral tegmental area, 901
opiate analgesics, 107
phencyclidine, 341
physostigmine, 1295
primates, 823
procaine, 1295
reward deprivation, 563
rhesus monkeys, 341
satiety, 341
schedule-induced behavior, 523
tether restraint for catheterization, 823
tobacco, 155
water deprivation, 563
Self-biting, 613
amphetamine
caffeine
haloperidol
pimozide
Self-injection
acetaldehyde, 807
body weight, 807
food deprivation, 807
lesions, nucleus accumbens septum, 579
lesions, 6-OHDA, 579
nicotine, 579
photoperiod, 807
schedule-controlled responding, 807
schedule-induced behavior, 579
Self-stimulation
atropine, 851
benzotropine, 851
p-chlorophenylalanine, 597
^{14}C-2-deoxyglucose autoradiography, 841
diagonal band of Broca, 841
diphenhydramine, 851
dopamine, 769
extinction, 769
haloperidol, 851
lateral habenula, 841
medial forebrain bundle, 841
medial raphe nucleus, 597
neuroleptics, 769
pimozide, 769, 783, 841
priming, 783
reinforcement, 769, 783, 841
serotonin, 597
time course analysis, 597
ventral tegmentum, 841
Sensitivity, 25
d-amphetamine
fluphenazine decanoate
locomotor activity
serum prolactin
Sensitization, 413
acoustic startle
d-amphetamine
schizophrenia, etiology
stress
Septum
cat, 297
entorhinal cortex, 77
6-hydroxydopamine, 77
lesions, A10, 77
morphine-induced behavior, 297
naloxone, 297
opiate receptors, 297
opioid peptides, 297
passive avoidance, 77

tree shrews, 77
tyrosine hydroxylase, 77
Serial learning, 165
acquisition deficits
cognition
diazepam
free recall
human studies
paired-associate learning
serial position effects
Serial position effects, 165
acquisition deficits
cognition
diazepam
free recall
human studies
paired-associate learning
serial learning
Serotonin
aggression, shock-induced, 945
amino acids, 939
antidepressants, 847
apomorphine, 393
cancer anorexia, 1043
p-chlorophenylalanine, 597, 945, 1043
cholinergic receptors, 159
depression, 159
dopamine, 1043
dopaminergic action, 393
drug discrmination, 393
eating, 1043
haloperidol, 393
5-hydroxyindoleacetic acid, 1043
hypothalamic-pituitary-adrenal axis, 721
imipramine, 159
inescapable shock, 877
learned helplessness, 877
medial raphe nucleus, 597
methysergide, 393, 597
muricide, 847
narcotic analgesics, 1155
neuroleptics, 1155
noradrenaline, 1155
norepinephrine, 721, 1043
obesity, genetic, 939
plasma corticosterone, 721
prenatal stress, 721
pressing responses, 945
quipazine, 393
R 18503, 1155
self-stimulation, 597
suicide, 159
time course analysis, 597
tryptophan, 877, 939, 1043
withdrawal, 1155
Zucker rats, 939
Serotonin metabolism, 49
environmental influences
housing, group
housing, isolation
valproic acid
Serum prolactin, 25
d-amphetamine
fluphenazine decanoate
locomotor activity
sensitivity
Sex differences
alcohol, 961
catecholamine excretion, 555
corticosterone, 1077
cortisol excretion, 555
defecation, 961
emotionality, 961, 1077
genetic differences, 961
human studies, 555
locomotor activity, 1077
open field, 1077
open field reactivity, 961
prenatal nicotine, 1077
rearing, 1077
response consistency, 555
stress, 555
Sexual behavior, 659
development
estrous cycle
malnutrition, postnatal
malnutrition, prenatal
Sexual behavior, birds, 405
biochanin A
dietary supplements
ferulic acid
quail
Sham feeding, 863
atropine methyl nitrate
cholinergic blockade
diet palatability
hunger
Sidman avoidance response, 425
central acting drugs
strain differences
Sign tracking, 665
pimozide
place preference
secondary reinforcement
Sleep, 797
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417)
cholinergic mechanisms
hypothalamus
pentobarbital antagonists
TRH
Sleep latency, 65
human studies
sleep quality
valerian
Sleep quality, 65
human studies
sleep latency
valerian
Social behavior
amphetamine, 1305
aggressive behavior, 691
apomorphine, 1305
dopamine, 1305
gerbils, 1305
isolation housing, 691
naloxone, 905
neurotransmitters, 1305
opiate antagonists, 691
pimozide, 1305
play fighting, 905
stereotypy, 1305
Social behavior, male baboons, 209
baboons
hashish
Social interaction, 623
aggression
anxiety
lesions, septum
neurotoxins
Sociosexual behavior, male mice, 1181
locomotor activity
mice, male
opiates
Sodium barbitone, 909
appetitive tasks
aversive tasks
learning
memory, long-term
Y-maze

^{99m}Tc-sodium pertechnetate, 1199
blood-brain barrier
central nervous system
α-MSH
Spatial behavior, 137
caffeine
early development
jewel fish
Spontaneous activity, 347
diprenorphine
naloxone
narcotic antagonists
Squirrel monkeys
behavior, 111
blood alcohol levels, 111
drinking, 1275
endorphins, 1275
ethanol, 111
milk intake, 1275
opiate agonists, 1275
opiate antagonists, 1275
opiate receptors, 1275
oral intubation, 111
pregnancy, 111
primates, 1275
Squirrel monkeys, male, 645
anxiolytic agents
benzodiazepines
conflict test
ethanol
meprobamate
phenobarbital
Starvation, 249
adipsia
anorexia
drinking
eating
hypothalamus
TRH
Stereospecifity, 291
drug discrimination
ketamine
phencyclidine
schedule-controlled behavior
Stereotyped behavior, 873
apomorphine
quantitative behavioral analysis
Stereotypy
amphetamine, 547, 1305
apomorphine, 967, 1035
behavioral augmentation, 547
dopamine, 1305
dopamine receptors, 967
gerbils, 1305
locomotor activity, 547, 967
neurotransmitters, 1305
pimozide, 967, 1305
repeated administration, 547
social behavior, 1305
strain differences, 967
sympathomimetics, 547
Stress
acoustic startle, 413
aggregation toxicity, 467
aggressive behavior, 1291
d-amphetamine, 413
body temperature, 119
catecholamine excretion, 555
catecholamines, 467
cerebellum, 1067
p-chloroamphetamine, 467
corticosterone, 1067
cortisol excretion, 555
cyclic AMP, 1067
cyclic GMP, 1067
dopaminergic agents, s21
environmental effects, 467
escape performance, 263
extinction, 229
growth hormone, 1067
haloperidol, 263
human studies, 555
hypothermia, ethanol-induced, 119
inescapable shock, 263
isolation syndrome, 1291
morphine analgesia, 229
naloxone, 119
nociception, 229
phenylethylamine, 1291
pituitary, 1067
prolactin, 1067
response consistency, 555
schizophrenia, etiology, 413
sensitization, 413
sex differences, 555
time, s21
tolerance, 229
tyramine, 1291
Strain differences
apomorphine, 967
apomorphine stereotypy, 1115
central acting drugs, 425
dopamine receptors, 967
locomotor activity, 967, 1115
pimozide, 967
Sidman avoidance response, 425
stereotypy, 967
striatal dopamine receptors, 1115
Streptomycin, 363
aminoglycosides
hair cells
ototoxicity
schooling behavior
tadpoles
Striatal dopamine receptors, 1115
apomorphine stereotypy
locomotor activity
strain differences
Striatum
amphetamine, 445
glutamic acid diethylester, 715
intracerebral electrochemistry, 445
kainic acid, 715
locomotion, 445
N-methyl-D-aspartate, 715
morphine, 715
muscular rigidity, 715
nucleus accumbens, 445
quisqualic acid, 715
Structure-activity relationships
amphetamines, 603
discriminative stimulus properties, 603
dopamine receptor agonists, s11
hallucinogens, 603
methoxyphenylisopropylamines, 603
phenylisopropylamines, 603
Subacute administration, 461
acute administration
antidepressants
kindling, amygdaloid
seizures
Substantia nigra
amphetamine, 431
brain stimulation, 431
circling behavior, 431
dopaminergic system, 431
evoked potentials, 1061
neuroleptics, 1061
oral dyskinesia, 1061
pimozide, 431

tardive dyskinesia, 1061
Sucrose, 333
concurrent schedules
ethanol reinforced responding
Suicide, 159
cholinergic receptors
depression
imipramine
serotonin
Superior colliculus, 1313
albino rats
ethyl alcohol
photic evoked potentials
visual cortex
Supersensitivity, 489
chronic administration
motor activity
narcotics
Sustained release, 183
blood levels
body temperature
Implantable Nicotine Reservoir
nicotine
Sympathomimetics, 547
amphetamine
behavioral augmentation
locomotor activity
repeated administration
stereotypy
Synergism, 589
cats
cross-tolerance
limb-flicks
LSD
tactile stimulus

Tactile stimulus, 589
cats
cross-tolerance
limb-flicks
LSD
synergism
Tadpoles, 363
aminoglycosides
hair cells
ototoxicity
schooling behavior
streptomycin
Tail-flick test
analgesia, 1161, 1213
dose-response relationships, 1213
Formalin test, 1213
morphine, 1161
morphine tolerance, 1213
prenatal exposure, 1161
Tardive dyskinesia, 1061
evoked potentials
neuroleptics
oral dyskinesia
substantia nigra
Taste, 323
estrous cycle
ethanol preference
lactation
ovariectomy
pregnancy
reproductive state, female rat
Temperature, 1203
ACTH
corticotropin releasing factor (CRF)
β-endorphin
hypothermia
α-MSH
naloxone
ptosis
reserpine
sedation
Testosterone, 681
castration
flupenthixol
haloperidol
luteinizing hormone
Tether restraint, 823
baboons
cocaine
primates
self-administration
Tetrabenzine, 995
dopaminergic agonists
haloperidol
α-methylparatyrosine
pigeons
piribedil
scheduled responding
Tetrahydroisoquinolines, 813
cortical neurons
Met-enkephalin
ethanol
hippocampal pyramidal neurons
naloxone
opiates
salsolinol
tetrahydropapaveroline
Tetrahydropapaveroline, 813
cortical neurons
Met-enkephalin
ethanol
hippocampal pyramidal neurons
naloxone
opiates
salsolinol
tetrahydroisoquinolines
Thermoregulation, 1001
acetylcholinesterase reactivation
conditioned avoidance
DFP
oximes
PAM
proPAM
Thiothixene, 1049
antipsychotics
clozapine
collateral behavior
drinking
eating
haloperidol
operant behavior
rabbits
schedule-induced behavior
scheduled responding
Thirst, hypervolemic, 921
chlordiazepoxide
naltrexone
thirst, osmotic
Thirst, osmotic, 921
chlordiazepoxide
naltrexone
thirst, hypovolemic
Thyrotropin-releasing hormone (TRH)
adipsia, 249
anorexia, 249
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide citrate (DN-1417), 797
cholinergic mechanisms, 797
drinking, 249
eating, 249
hypothalamus, 249, 797
pentobarbital antagonists, 797
starvation, 249

Time, s21
dopaminergic agents
stress
Time course analysis, 597
p-chlorophenylalanine
medial raphe nucleus
self-stimulation
serotonin
T-maze, 473
brain development
corticosteroids
neonates, rats
radial maze
triamocinolone acetonide
Tobacco, 155
cigarette smoking
human studies
self-administration
Tofizopam, 367
benzodiazepine receptors
diazepam
Tolerance
antagonism, 223
benzodiazepines, 43
chlordiazepoxide, 1239
discriminative stimulus properties, 223
drug experience effects, 43
ethanol, 1073, 1239
extinction, 229
Geller-Seifter conflict test, 43
genetic differences, 1073
individual variability, 43
morphine, 223
morphine analgesia, 229
naloxone, 223
nociception, 229
oxazepam, 43
physical dependence, 1239
pigeons, 223
rate dependency, 43
stress, 229
withdrawal, 1239

Transfer, 1111
kindling
pentylenetetrazol
seizures
Trazodone, 1221
amitriptyline
blood pressure
cardiovascular system
heart rate
iprindole
Tree shrews, 77
entorhinal cortex
6-hydroxydopamine
lesions, A10
passive avoidance
septum
tyrosine hydroxylase
Triamcinolone acetonide, 473
brain development
corticosteroids
neonates, rats
radial maze
T-maze
Triazolopyridazines, 709
benzodiazepines
chlordiazepoxide
drug discrimination
Tripelennamine, 789
drug discrmination
drug interaction
morphine
naloxone
N-allyl normetazocine (SKF 10,047)
pentozocine
TRS-80 microcomputer, 583
BASIC
behavioral pharmacology
operant research
Tryptophan
amino acids, 939
cancer anorexia, 1043
p-chlorophenylalanine, 1043
dopamine, 1043
eating, 1043
5-hydroxyindoleacetic acid, 1043
inescapable shock, 877
learned helplessness, 877
methysergide, 877
norepinephrine, 1043
obesity, genetic, 939
serotonin, 877, 939, 1043
Zucker rats, 939
Tyramine, 1291
aggressive behavior
isolation syndrome
phenylethylamine
stress
Tyrosine hydroxylase, 77
entorhinal cortex
6-hydroxydopamine
lesions, A10
passive avoidance
septum
tree shrews

Urine outflow, 1265
aspartic acid
core temperature
drinking
eating

Vagal afferents, 19
cardiovascular reflex
D-Ala^2-Met^5-enkephalinamide
morphine
motor activity
phenyldiguanide
pulmonary J-receptors
pulmonary opiate receptors
Vaginal patency, 629
chronic ethanol
estrous cycle, female rats
ovarian function
pregnant rats
Valerian, 65
human studies
sleep latency
sleep quality
Valproic acid, 49
environmental influences
housing, group
housing, isolation
serotonin metabolism
Vascular stroke, 1083
gerbils
MIF-1
naloxone
opiate antagonists
Vasopressin, 685
ethanol tolerance
neurohypophyseal peptides
Vasopressin analogues, 1123
d-amphetamine
1-desamino-8-D-arginine
matching-to-sample

memory, short-term
pigeons
scopolamine
Ventral tegmental nuclei of Gudden, 973
benzodiazepines
GABA
5-hydroxytryptamine
locomotor activity
muscimol
Ventral tegmentum, 841
^{14}C-2-deoxyglucose autoradiography
diagonal band of Broca
lateral habenula
medial forebrain bundle
pimozide
reinforcement
self-stimulation
Ventromedial hypothalamus, 1141
eating
hyperthermia
morphine
opiate receptors
Visual cortex, 1313
albino rats
ethyl alcohol
photic evoked potentials
superior colliculus
Visual evoked response, 915
attention
cigarette smoking
human studies
nicotine

Water deficits, 955
2-deoxy-D-glucose
drinking
eating
glucoprivation
Water deprivation, 563
dose response
food deprivation
reward deprivation
self-administration
Withdrawal
age differences, 1037
chlordiazepoxide, 1239
ethanol, 125, 1037, 1239
fetal alcohol syndrome, animal model, 125
intoxication, 1037
maternal behavior, female rat, 125
narcotic analgesics, 1155
neuroleptics, 1155
noradrenaline, 1155
physical dependence, 1239
pregnancy, 125
R 18 503, 1155
serotonin, 1155
tolerance, 1239
Withdrawal syndrome
clonidine, 655
conditioned taste preference, 609
ethanol dependence, 609
methylxanthines, 655
naloxone, 655

Y-Maze, 909
appetitive tasks
aversive tasks
learning
memory, long-term
sodium barbitone

Zucker rats, 939
amino acids
obesity, genetic
serotonin
tryptophan

Pharmacology Biochemistry & Behavior, Vol. 17. Copyright © 1982 by Ankho International Inc. Printed in the U.S.A.

AUTHOR INDEX

ABBOTT, F. V., 1213
ABEL, M. S., 159
AIRAKSINEN, M. M., 831
AMIT, Z., 233
ANDERSON, G. M., 1281
ANISMAN, H., 263, 1245
ANTELMAN, S., s21
ANTKIEWICZ-MICHALUK, L., 1115
ARMBRECHT, H. J., 1037
ARNERIC, S. P., s11
ARNOULT, D. E., 583
ASHCRAFT, L. J., 1019
ASHKENAZI, R., s43
ASHTON, D., 1155

BABBINI, M., 43
BAETTIG, K., 915
BAKER, M. J., 389
BALSTER, R. L., 291, 1181
BALTRUS, B. M., 1061
BANDO, Y., 519
BANKS, W. A., 1009, 1187
BARRETT, J. E., 1049
BARTOLETTI, M., 43
BARTOLINI, L., 933
BAUM, M. J., 857
BAUMANN, J. B., 511
BAYORH, M. A., 699
BEATTY, W. W., 905
BEDFORD, J. A., 1087
BEER, B., 159
BELESLIN, D. B., 371, 1317
BEN-SHACHAR, D., s43
BERGER, T., 813
BERIE, J. L., 165
BERKMAN, K., 1265
BHATNAGAR, R. K., s11
BIANCHINE, J. R., 1233
BIDERMAN, M. D., 955
BIDZIŃSKI, A., 619
BLOOM, F. E., 813
BO, W. J., 629
BODNAR, R. J., 1175
BOE, I. N., 563
BONNET, K. A., 677
BOSH, T. K., 651
BOULTON, A. A., 1291
BOYTIM, M., 769
BOZARTH, M. A., 239
BRADFORD, L. D., 823
BRADY, J. V., 823
BRADY, K. T., 291
BREESE, G. R., 681
BROWN, D. R., 1275
BROWN, L., 877
BROWN, Z. W., 233
BROWNE, R. G., 547
BUNNELL, B. N., 1067
BUREŠOVÁ, O., 1129
BURGESS, J. W., 137

CAIN, D. P., 1111
CAIN, M., 457
CAIRNIE, A. B., 305
CANNON, J. G., s11
CANTALAMESSA, F., 741
CAREY, R. J., 851
CARLI, M., 1
CARROLL, M. E., 341, 563
CARTER, R. B., 223
CASAMENTI, F., 933
CASBEER, D., 1239
CASTELLANOS, P. F., 1187
CHAIT, L. D., 155
CHAN, A. W. K., 141, 1239
CHAN, E., 639
CHANCE, W. T., 939, 1043
CHAPIN, R. E., 681
CHAUFFARD, F., 65
CHEAL, M. L., 1305
CHEREK, D. R., 523
CHERKIN, A., 893
CHIU, E. K. Y., 1221
CLARKE, A., 623
CLEARY, J. P., 945
CLODY, D., 847
COHEN, D. J., 1281
COLLINS, A. C., 91, 245
COLLINS, R. J., 107
CONCANNON, J. T., 5, 393
COOK, J., 457
COOLS, A. R., 297
COPPER, S. J., 481, 921
CORNISH, K. G., 1285
CORRADINI, A., 1245
COSCINA, D. V., 1145
COSTELLO, K. B., 905
COUPET, J., 159
COY, D. H., 15, 633, 1009, 1187, 1193, 1203
CREESE, I., 375
CRISP, T., 589

DALEY, L., 823
DAVIDSON, A. B., 385
DAVIS, B. A., 1291
DAVIS, J. L., 893
DAVIS, W. M., 489
DEAN, P., 873
DE CARO, G., 741
DELORENZO, R., 823
DE MAN, E., 405
DEPAULIS, A., 451
DEROSSETT, S. E., 347, 1161
DERYCK, M., 1027
DESJARDINS, P. J., 1055
DE WIED, D., 177
DE WITTE, PH., 1093
DIETZ, P. E., 171
DOURISH, C. T., 1291
DRUGAN, R. C., 1019
DUNN, A. J., 31, 37
DUNWIDDIE, T. V., 1257
DYCK, L. E., 1291
DYKSTRA, L. A., 223

EHRENSING, R. H., 757
EISENSTEIN, N., 847
EISON, A. S., s25
EISON, M. S., s25
ELLINGBOE, J., 171
ELSOHLY, H. N., 1087
EMMETT-OGLESBY, M. W., 583
ERICKSON, C. K., 183
ERIKSSON, C. J. P., 831
ERSKINE, M. S., 857
ETKIN, M. W., 915
EVANS, H. L., 1123

FABRE, L. A., 1199
FAUSTMAN, W. O., 987
FEKETE, M., 177
FELDMAN, R. S., 709
FELLEMAN, V. H., 399
FENTON, H. M., 1207
FERNANDEZ, S., 659
FIBIGER, H. C., 359, 639
FILE, S. E., 623, 1165
FINKELSTEIN, J. A., 939
FISCHER, J. E., 939, 1043
FLOREZ-LOZANO, J., 659
FLYNN, J., s11
FOLTIN, R. W., 1089
FORGER, N. G., 323, 529
FORSMAN, L., 555
FOWLER, S. C., 987
FRANKLIN, K. B. J., 431
FREEDMAN, L. S., 187
FREGLY, M. J., 727
FRENCH, E. D., 813
FREUND, G., 313
FUNG, Y. K., 651

GAIARDI, M., 43
GALLAGHER, M., 217
GALLISTEL, C. R., 769, 783, 841
GALLUS, J. A., 467, 945, 1225
GARZA, R. DE LA 1295
GATTI, P., 19
GAULT, F. P., 467, 945
GERTNER, S. B., 19
GHONEIM, M. M., 165
GIANUTSOS, G., 951
GILES, T. D., 1301
GILMORE, J. P., 1285
GIRARD, J., 511
GLASSMAN, H. N., 1061
GLASSMAN, R. B., 1061
GLENNON, R. A., 603
GOLDSTEIN, J. M., 461
GOLUB, M. S., 473
GOMITA, Y., 769, 783, 841
GÖTESTAM, K. G., 1171

Numbers preceded by the letter s indicate items appearing in *Dopamine Receptors and Their Behavioral Correlates*, Suppl. 1, Vol. 17, 1982.

GOY, H. B., 1097
GRAF, M., 511
GRANDMAISON, L. J., 665
GRANT, S. J., 655
GRASSMAN, D. R., 651
GRATTON, A., 597
GRAU, J. W., 1019
GRECKSCH, G., 11
GREENLEAF, J. E., 727
GREENSHAW, A. J., 1129
GREIZERSTEIN, H. B., 141
GRIFFITHS, R. R., 155, 823
GRISOLÍA, S., 927
GUERRI, C., 927
GUILD, A. L., 31

HALL, R., 579
HALPERN, B., 1149
HAMANN, S. R., 1271
HANNIGAN, J. H., JR., 193
HARRIS, P. F., 1119
HARRY, G. J., 915
HASHIMOTO, H., 131
HAUG, T., 1171
HAUPTMANN, M., 619
HAVEMANN, U., 715
HAYASHI, T., 131
HEBERT, D., 703
HECK, E., 65
HEILBRONNER, R. L., 1313
HELLSTRÖM, E., 1103
HELPS, S. C., 885
HEMMER, R. C., 1287
HEMNANI, K. L., 489
HENNESSY, M. B., 111
HETZLER, B. E., 1313
HILL, L. G. J., 125
HINRICHS, J. V., 165
HIRST, M., 1141
HOFFER, B., 569
HOFFMAN, P. L., 685
HLTZMAN, S. G., 347, 1161, 1275
HONOUR, L. C., 1203
HOOD, J. L., 389
HOWD, R. A., III, 1001
HOWERTON, T. C., 245
HRUSKA, R. E., 1027
HUOT, S., 99
HURD, R. W., 37
HYSON, R. L., 1019

IORIO, L. C., 847
ISAACSON, R. L., 193

JALFRE, M., 1309
JÄRBE, T. U. C., 671
JOHANSON, C. E., 1295
JOHNELS, B., 283
JOHNSON, K. M., 53
JONES, R. S. G., 1291
JORK, R., 11, 203
JOYNER, W. L., 1285
JUDGE, M. E., 187, 677
JUSTICE, J. B., 445

KALLMAN, M. J., 915
KALLMAN, W. M., 915
KAMERLING, S. G., 733
KAMEYAMA, T., 59
KANT, G. J., 1067
KAPLAN, J. N., 111
KAPP, B. S., 217
KASTIN, A. J., 757, 1009, 1083, 1187, 1193, 1199, 1203, 1287, 1301
KEMPF, E., 49
KENLEY, R. A., 1001
KENNEY, N. J., 73
KIIANMAA, K., 1073
KIKTA, D. C., 727
KIRBY, M. L., 1161
KIRCHGESSNER, A. L., 1175
KISARA, K., 249
KLEBANOFF, L., 769
KNOBLOCH, L. C., 461
KOCH, K. I., 183
KOHNO, H., 249
KOIKE, Y., 519
KOJER, G., 77
KOKKINIDIS, L., 413
KOOB, G. F., 901, 1015
KORCZYN, A. D., 897
KOSTOWSKI, W., 619
KOYUNCUOĞLU, H., 1265
KRIEG, E. F., JR., 1193
KRSTIĆ, S. K., 371, 1317
KRUEGER, W. A., 629
KRUK, M. R., 147
KUBANIS, P., 313
KUCZENSKI, R., 375, 547
KUPRYS, R., 271
KURIBARA, H., 425, 1251
KURKULOS, M. E., 1305
KUSCHINSKY, K., 715

LAHTI, R. A., 107
LANDAUER, M. R., 1181
LAYNG, M. P., 389
LEACH, K. E., 305
LEANDER, J. D., 995
LEATHWOOD, P. D., 65
LEBER, B. F., 1213
LEE, C., 1149
LEE, T. M., 1149
LEITE, J. R., 909
LE MAGNEN, J., 609
LENOX, R. H., 1067
LEONG, F. W., 1239
LERNER, S. A., 363
LEWIS, G., 873
LI, T.-K., 763
LIEBMAN, J. M., 1207
LIGHT, S., 951
LINDSAY, W. S., 445
LIPPA, A. S., 159
LOCKE, K. W., 1275
LO CONTE, G., 933
LONG, J. P., s11
LORDEN, J. F., 435
LORENS, S. A., 973
LÖSSNER, B., 203
LUKAS, S. E., 823
LUM, A. M., 363
LUMENG, L., 763
LUNDBERG, U., 555

McBRIDE, W. J., 763
McDONOUGH, J. H., JR., 85
McELROY, J. F., 709
McGINITY, J. W., 183
McLEAN, J. H., 1287

MACK, G., 49
MACNEILL, E. P., 413
MAIER, S. F., 1019
MALICK, J. B., 461
MALIN, D. H., 389
MANDEL, P., 49, 691
MANN, M. A., 837
MAOR, D., 897
MARCONCINI-PEPEU, I., 933
MARFAING-JALLAT, P., 609
MARÍN, B., 659
MARTIN, W. R., 733
MARTIN-IVERSON, M. T., 639
MASSI, M., 741
MATTHIES, H., 11, 203
MEANS, L. W., 125, 1097
MEELIS, W., 147
MEGENS, A. A. P. H., 297
MELTZER, H. Y., s1
MELZACK, R., 1213
MENDELSON, J. H., 171
MENENDEZ-PATTERSON, A., 659
MERALI, Z., 25
MESSENGER, M., 885
MEWALDT, S. P., 165
VON MEYENFELDT, M., 1043
MEYERHOFF, J. L., 1067
MICHAEL, S. D., 837
MICHALUK, J., 1115
MICHELL, G. F., 757
MICOSSI, L. G., 741
MICZEK, K. A., 503
MIGLER, B., 645
MINAMI, M., 519
MIYAMOTO, M., 797
MOE, K. E., 73
MOERSCHBAECHER, J. M., 353, 1055
MOLLENAUER, S., 381
MOLTZ, H., 1149
MORIN, L. P., 323, 529
MORROW, G., 951
MORTON, E. C., 539
MOS, J., 147
MUELLER, K., 613
MUELLER, R. A., 681
MUNOZ-BOX, R., 65
MYERS, R. D., 1271
MYERS, W. D., 807
MYERSON, L. R., 159

NAGAI, Y., 797
NAGASAKA, M., 59
NAGAWA, Y., 797
NAKASHIMA, M., 131
NANRY, K. P., 1225
NARUMI, S., 797
NEARCHOUS, N. I., 467
NEILL, D. B., 445
NG, K. T., 807
NISSEN, C., 1083, 1187
NOBREGA, J. N., 1145
NOVIN-BAHERAN, A., 651
NUNN, W. B., 435
NYHAN, W. L., 613

OAKLAY, K. E., 1313
O'CONNOR, M. F., 245
OELTGEN, P. R., 1271
OLIVERIO, A., 691, 967, 1115
OLIVIER, B., 147
OLSON, G. A., 1287
OLSON, R. D., 1083, 1287
OLTMANS, G. A., 271
ORBACH, J., 1119
OVERSTREET, D. H., 885, 1119

PACE, H. B., 489
PALFAI, T., 399
PALFREYMAN, M. G., 99
PALMER, M., 569
PALMOUR, R., 613
PASCOE, J. P., 217
PASTERNAK, G. W., 1175

PATEL, J. B., 645
PAUL, S. M., s37, 457
PEEKE, H. V. S., 405
PEPEU, G., 933
PERT, C. B., 699
PETERS, D. A. V., 721, 1077
PEURA, P., 831
PHILLIS, J. W., 749
PICO, R. M., 893
PINEL, J. P. J., 359
PIPKIN, B., 381
PISA, M., 639
PŁAZNIK, A., 619
PLOTNIK, R., 381
POPOV, N., 203
PORSOLT, R. D., 1309
POTEL, M. J., 363
PRASAD, V., 377
PROCTOR, C., 229
PUCIŁOWSKI, O., 619
PUGLISI-ALLEGRA, S., 691

QUARTERMAIN, D., 187, 677
QUIRION, R., 699

RAAB, A., 77
RANDALL, D. C., 1271
RANDT, C. T., 677
RAUH, C. E., 159
REDGRAVE, P., 873
REDMOND, D. E., JR., 655
REGAN, S. G., 119
REINSTEIN, D. K., 193
RIBLET, L. A., s25
RICHARDSON, A. K., 855
RICHARDSON, J. S., 855, 1221
RILEY, E. P., 877
ROBERSON, N. L., 1257
ROBERTS, D. C. S., 901, 1015
RODGERS, R. J., 451
RÖNNBÄCK, L., 495
ROEHRS, T. A., 333
ROKOSZ-PELC, A., 1115
RONDEAU, D. B., 703
ROSECRANS, J. A., 915
ROSELLINI, R. A., 877
ROSENGREN, L., 495
ROUX, S., 1309
RUDEEN, P. K., 629
RUSSELL, R. W., 885

SAANO, V., 367
SABODA, S., 613
SAINATI, S. M., 973
SAITO, H., 519
SAJI, Y., 797
SAKURADA, T., 249
SALAMONE, J. D., 445
SAMANIN, R., 1
SAMARDŽIĆ, R., 1317
SAMSON, H. H., 333
SAMUELS, O. B., 877
SANDER, G. E., 1301
SANSONE, M., 967, 1115
SAPRU, H. N., 19
SATINDER, K. P., 961
SCHALLY, A. V., 15, 633
SCHANLEY, D. L., 1239
SCHECHTER, M. D., 5, 393
SCHLEEF, C., 49
SCHMIDT, S., 203
SCHOENENBERGER, G. A., 511
SCHULZECK, S., 203
SCHWARZ, R. D., 1233
SCHWERI, M., 457
SEGAL, D. S., 375, 547
SEWELL, R. G., JR., 467, 945, 1225
SHANNON, H. E., 789
SHAYWITZ, B. A., 1281
SHEARD, M. H., 377
SHERMAN, J. E., 229
SHIER, W. T., 813
SHIMAMURA, K., 519
SIEBER, B., 209
SIGGINS, G. R., 813
SILBERGELD, E. K., 1027
SILVA, L., 1305
SINGER, G., 579, 807
SKOLNICK, P., s37, 457
SLOAN, J. W., 733
SMITH, G. C., 1135
SMOLEN, A., 91
SMOLEN, T. N., 91
SPENCER, D. G., JR., 583
SPOERLEIN, M. T., 419
SPUHLER, K., 569
SPURRIER, W. A., 1271
STANTON, H. C., s25
STAVCHANSKY, S. A., 183
STEFANOVIĆ-DENIĆ, K., 371
STRAUSS, W., 141
STRECKER, R. E., 1015
STRUB, H., 229
SU, T.-P., 733, 789
SUEIRAS-DIAZ, J., 1203
SUZUKI, T., 249
SVARE, B., 837
SWANK, P., 389
SWEENEY, M. J., 951

TABAKOFF, B., 1073
TADANO, T., 249
TADOKORO, S., 131, 1251
TANG, S., 1077
TAUKULIS, H. K., 695
TAYLOR, D. P., s25
TEAL, J. J., 1123
TEICHER, M. H., 1281
TELEGDY, G., 15, 633
TEMPLE, D. L., JR., s25
TEPPERMAN, F. S., 1141
THOMAS, J. R., 1055
THOMPSON, D. M., 353, 1055
TOBLER, H. J., 511
TOGASHI, H., 519
TOLLIVER, G. A., 333
TOMBAUGH, T. N., 665, 1245
TOMAZ, C. A. B., 909
TOTH, G., 25
TOTTMAR, O., 1103
TOWELL, A., 255
TREIT, D., 359
TRULSON, M. E., 589
TUOMISTO, L., 831
TURCOTTE, M., 703
TURNER, C. E., 1087
TURSKI, L., 715
TYLER, C. B., 503

URETSKY, N. J., 1233
URTTI, A., 367
UYENO, E. T., 1001
VACCARINO, F. J., 431
VALLANO, M. L., 419
VAN AKEN, J. H. M., 147
VAN DER POEL, A. M., 147
VANDERWENDE, C., 419
VAUPEL, D. B., 539
VÉCSEI, L., 15, 633
VENTURA, D. F., 909
VESTAL, T., 1313
VETULANI, J., 967, 1115

WALLACE, M., 579
WALLER, M. B., 763
WALSH, J. W., 1271
WASSERMAN, E. M., 783
WASSERSUG, R. J., 363
WATSON, P. J., 955
WATSON, S. D., 863
WAUQUIER, A., 1155
WEINBERGER, S. B., 547
WEINER, N., 569
WEINGARTEN, H. P., 863
WELDON, D. A., 1281
WENNOGLE, L. P., 159
WETTSTEIN, J. G., 733
WHITE, M., 381
WILLETTE, R. N., 19
WILLIS, G. L., 1135
WILLNER, P., 255
WISE, R. A., 239
WISE, R. W., 1037
WITKIN, J. M., 223
WOOD, W. G., 1037
WOODSON, P. P., 915
WOOL, R. S., 1281
WORTH, T., 1257
WRONSKI, A., 495
WU, P. H., 749

YORK, J. L., 119
YOUDIM, M. B. H., s43
YOUNG, L., 703
YOUNG, R., 603
YUEN, H., 749
ZACHARKO, R. M., 263, 1245
ZADINA, J., 1193
ZERBE, R. L., 699
ZEUCHNER, J., 495
ZITO, K. A., 665
ZORNETZER, S. F., 313

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 1 JULY 1982

CONTENTS

Evidence that agents increasing water consumption do not necessarily generate "falsh positives" in conflict procedures using water as a reinforcer. CARLI, M. and R. SAMANIN 1

Failure of amphetamine isomers to decrease hyperactivity in developing rats. CONCANNON, J. T. and M. D. SCHECHTER 5

Apomorphine and glycoprotein synthesis during consolidation. JORK, R., G. GRECKSCH and H. MATTHIES 11

The interaction between β-[Tyr^9]melanotropin-(9–18), haloperidol and amphetamine in different behavior tests of rats. TELEGDY, G., L. VÉCSEI, A. V. SCHALLY and D. H. COY 15

Pulmonary vagal afferent stimulants in the conscious rat: Opioids and phenyldiguanide. WILLETTE, R. N., P. GATTI, S. B. GERTNER and H. N. SAPRU 19

Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. MERALI, Z. and G. TOTH 25

Dopamine involvement in ACTH-induced grooming behavior. GUILD, A. L. and A. J. DUNN 31

Regional glucose metabolism in mouse brain following ACTH peptides and naloxone. DUNN, A. J. and R. W. HURD 37

Benzodiazepine effects upon Geller-Seifter conflict test in rats: Analysis of individual variability. BABBINI, M., M. GAIARDI and M. BARTOLETTI 43

Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. KEMPF, E., G. MACK, C. SCHLEEF and P. MANDEL 49

Phencyclidine: Behavioral and biochemical evidence against the anticholinergic hypothesis. JOHNSON, K. M. 53

Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. KAMEYAMA, T. and M. NAGASAKA 59

Aqueous extract of valerian root (*Valeriana officinalis L.*) improves sleep quality in man. LEATHWOOD, P. D., F. CHAUFFARD, E. HECK and R. MUNOZ-BOX 65

Cellular dehydration and hypovolemia: Effect of acetylsalicylic on drinking. KENNEY, N. J. and K. E. MOE 73

A10 lesion and passive avoidance latency: Correlation with limbic tyrosine-hydroxylase-activity. RAAB, A. and G. KOJER 77

Effects of anticholinergic drugs on DRL performance of rhesus monkeys. McDONOUGH, J. H., JR. 85

Seizure susceptibility of the pregnant mouse. SMOLEN, A., T. N. SMOLEN and A. C. COLLINS 91

Effects of γ-vinyl GABA on food intakes of rats. HUOT, S. and M. G. PALFREYMAN 99

Opiate effects on plasma corticosteroids: Relationship to dysphoria and self-administration. LAHTI, R. A. and R. J. COLLINS 107

Oral ethanol intake and levels of blood alcohol in the squirrel monkey. KAPLAN, J. N., M. B. HENNESSY and R. A. HOWD 111

Conditioned and unconditioned influences on body temperature and ethanol hypothermia in laboratory rats. YORK, J. L. and S. G. REGAN 119

Effects of alcohol consumption during pregnancy on subsequent maternal behaviour in rats. HILL, L. G. J. and L. W. MEANS 125

Enhancement of avoidance-suppressing effect after repeated administration of haloperidol and serum haloperidol in rats. HAYASHI, T., S. TADOKORO, H. HASHIMOTO and M. NAKASHIMA 131

Chronic exposure to caffeine during early development modifies spatial behavior in juvenile jewel fish schools. BURGESS, J. W. 137

Alcohol-chlordiazepoxide interaction. CHAN, A. W. K., H. B. GREIZERSTEIN and W. STRAUSS 141

Anti-aggressive effect of a new phenylpiperazine compound (DU27716) on hypothalamically induced behavioural activities. VAN DER POEL, A. M., B. OLIVIER, J. MOS, M. R. KRUK, W. MEELIS and J. H. M. VAN AKEN 147

Differential control of puff duration and interpuff interval in cigarette smokers. CHAIT, L. D. and R. R. GRIFFITHS 155

Human brain receptor alterations in suicidal victims. MEYERSON, L. R., L. P. WENNOGLE, M. S. ABEL, J. COUPET, A. S. LIPPA, C. E. RAUH and B. BEER 159

Diazepam and learning: Assessment of acquisition deficits. HINRICHS, J. V., S. P. MEWALDT, M. M. GHONEIM and J. L. BERIE 165

BRIEF COMMUNICATION

Postmortem plasma luteinizing hormone levels and antemortem violence. MENDELSON, J. H., P. E. DIETZ and J. ELLINGBOE 171

ANNOUNCEMENTS 175

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 2 AUGUST 1982

CONTENTS

Dose related facilitation and inhibition of passive avoidance behavior by the ACTH 4–9 analog (ORG 2766). FEKETE, M. and D. DE WIED 177

A new subcutaneously-implantable reservoir for sustained release of nicotine in the rat. ERICKSON, C. K., S. A. STAVCHANSKY, K. I. KOCH and J. W. McGINITY 183

Effects of cycloheximide, a protein synthesis inhibitor, on mouse brain catecholamine biochemistry. FREEDMAN, L. S., M. E. JUDGE and D. QUARTERMAIN 187

Time course of certain behavioral changes after hippocampal damage and their alteration by dopaminergic intervention into nucleus accumbens. REINSTEIN, D. K., J. H. HANNIGAN, JR. and R. L. ISAACSON 193

Mechanisms of dopamine induced changes in hippocampal glycoprotein metabolism. JORK, R., S. SCHMIDT, S. SCHULZECK, B. LÖSSNER, N. POPOV and H. MATTHIES 203

Influence of hashish extract on the social behaviour of encountering male baboons (*Papio c. anubis*). SIEBER, B. 209

Enkephalin analogue effects in the amygdala central nucleus on conditioned heart rate. GALLAGHER, M., B. S. KAPP and J. P. PASCOE 217

Acute tolerance to the discriminative stimulus properties of morphine. WITKIN, J. M., L. A. DYKSTRA and R. B. CARTER 223

Prior hot plate exposure enhances morphine analgesia in tolerant and drug-naive rats. SHERMAN, J. E., C. PROCTOR and H. STRUB 229

Actions of drugs of abuse on brain reward systems: A reconsideration with specific attention to alcohol. AMIT, Z. and Z. W. BROWN 233

Action of drugs of abuse on brain reward systems: An update with specific attention to opiates. WISE, R. A. and M. A. BOZARTH 239

Effects of pentobarbital in mice selected for differential sensitivity to ethanol. O'CONNOR, M. F., T. C. HOWERTON and A. C. COLLINS 245

Intracranial injection of thyrotropin releasing hormone (TRH) suppresses starvation-induced feeding and drinking in rats. SUZUKI, T., H. KOHNO, T. SAKURADA, T. TADANO and K. KISARA 249

Microstructural analysis of the involvement of beta-receptors in amphetamine anorexia. WILLNER, P. and A. TOWELL 255

Stimulus change influences escape performance: Deficits induced by uncontrollable stress and by haloperidol. ANISMAN, H. and R. M. ZACHARKO 263

Amphetamine anorexia and hypothalamic catecholamines in genetically obese mice (*obob*). KUPRYS, R. and G. A. OLTMANS 271

Locomotor hypokinesia in the reserpine-treated rat: Drug effects from the corpus striatum and nucleus accumbens. JOHNELS, B. 283

Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. BRADY, K. T. and R. L. BALSTER 291

Intraseptally injected opiate agents: Effects on morphine-induced behaviour of cats. MEGENS, A. A. P. H. and A. R. COOLS 297

Dexamethasone: A potent blocker for radiation-induced taste aversion in rats. CAIRNIE, A. B. and K. E. LEACH 305

Memory and postsynaptic cholinergic receptors in aging mice. KUBANIS, P., S. F. ZORNETZER and G. FREUND 313

Reproductive state modulates ethanol intake in rats: Effects of ovariectomy, ethanol concentration, estrous cycle and pregnancy. FORGER, N. G. and L. P. MORIN 323

Ethanol reinforced responding in the rat: A concurrent analysis using sucrose as the alternate choice. SAMSON, H. H., T. A. ROEHRS and G. A. TOLLIVER 333

Rapid acquisition of oral phencyclidine self-administration in food-deprived and food-satiated rhesus monkeys: Concurrent phencyclidine and water choice. CARROLL, M. E. 341

Effects of naloxone and diprenorphine on spontaneous activity in rats and mice. DEROSSETT, S. E. and S. G. HOLTZMAN 347

Phencyclidine in combination with pentobarbital: Supra-additive effects on complex operant behavior in pigeons. THOMPSON, D. M. and J. M. MOERSCHBAECHER 353

BRIEF COMMUNICATIONS

The inhibitory effect of diazepam on conditioned defensive burying is reversed by picrotoxin. TREIT, D., J. P. J. PINEL and H. C. FIBIGER 359

Schooling behavior of tadpoles: A potential indicator of ototoxicity. LUM, A. M., R. J. WASSERSUG, M. J. POTEL and S. A. LERNER 363

Tofizopam modulates the affinity of benzodiazepine receptors in the rat brain. SAANO, V. and A. URTTI 367

Effect of morphine and morphine-like drugs on carbachol-induced fighting in cats. KRSTIĆ, S. K., K. STEFANOVIĆ-DENIĆ and D. B. BELESLIN 371

Lack of behavioral evidence for dopamine autoreceptor subsensitivity after acute electroconvulsive shock. CREESE, I., R. KUCZENSKI and D. SEGAL 375

Effect of lithium upon desipramine enhanced shock-elicited fighting in rats. PRASAD, V. and M. H. SHEARD 377

ANNOUNCEMENTS 379

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 3 SEPTEMBER 1982

CONTENTS

Chronic amphetamine: Effects on defensive flight in the rat. MOLLENAUER, S., M. WHITE, R. PLOTNIK and B. PIPKIN 381

Effects of chlorpromazine on continuous avoidance behavior in mice. DAVIDSON, A. B. 385

Behavioral alterations produced by chronic naloxone injections. MALIN, D. H., M. P. LAYNG, P. SWANK, M. J. BAKER and J. L. HOOD 389

Dopaminergic activity of quipazine. SCHECHTER, M. D. and J. T. CONCANNON 393

Effect of age, clonidine or propranolol on behavioral toxicity induced with digitoxin in mice. PALFAI, T. and V. H. FELLEMAN 399

Dietary ferulic acid, biochanin A, and the inhibition of reproductive behavior in Japanese quail (*Coturnix coturnix*). DE MAN, E. and H. V. S. PEEKE 405

Stress-induced facilitation of acoustic startle after d-amphetamine administration. KOKKINIDIS, L. and E. P. MACNEILL 413

Morphine enhances high-affinity choline uptake in mouse striatum. VALLANO, M. L., M. T. SPOERLEIN and C. VANDERWENDE 419

Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats. KURIBARA, H. 425

Dopamine mediates ipsi- and contraversive circling elicited from the substantia nigra. VACCARINO, F. J. and K. B. J. FRANKLIN 431

Effects of central and peripheral pretreatment with fluoxetine in gustatory conditioning. LORDEN, J. F. and W. B. NUNN 435

Behavioral observation and intracerebral electrochemical recording following administration of amphetamine in rats. SALAMONE, J. D., W. S. LINDSAY, D. B. NEILL and J. B. JUSTICE 445

GABAergic influences on defensive fighting in rats. RODGERS, R. J. and A. DEPAULIS ... 451

Blockade of 3-carbomethoxy-β-carboline induced seizures by diazepam and the benzodiazepine antagonists, Ro 15-1788 and CGS 8216. SCHWERI, M., M. CAIN, J. COOK, S. PAUL and P. SKOLNICK 457

Effects of acute and subacute antidepressant treatment on kindled seizures in rats. KNOBLOCH, L. C., J. M. GOLDSTEIN and J. B. MALICK 461

Environmental determinants of parachloroamphetamine toxicity in rats. GALLUS, J. A., R. G. SEWELL, JR., N. I. NEARCHOUS and F. P. GAULT 467

Maze exploration in juvenile rats treated with corticosteroids during development. GOLUB, M. S. .. 473

Caffeine-induced hypodipsia in water-deprived rats: Relationships with benzodiazepine mechanisms. COOPER, S. J. 481

Motility response of rats to chronic constant-dose treatment with narcotics. DAVIS, W. M., K. L. HEMNANI and H. B. PACE 489

A new ingestion method for long-term morphine intoxication in rat. ZEUCHNER, J., L. ROSENGREN, A. WRONSKI and L. RÖNNBÄCK 495

Effects of phencyclidine on aggressive behavior in mice. TYLER, C. B. and K. A. MICZEK .. 503

DSIP-induced changes of the daily concentrations of brain neurotransmitters and plasma proteins in rats. GRAF, M., J. B. BAUMANN, J. GIRARD, H. J. TOBLER and G. A. SCHOENENBERGER 511

Effects of clonidine and guanfacine on drinking and ambulation in spontaneously hypertensive rats. TOGASHI, H., M. MINAMI, Y. BANDO, Y. KOIKE, K. SHIMAMURA and H. SAITO 519

Schedule-induced cigarette self-administration. CHEREK, D. R. 523

Endocrine control of ethanol intake by rats or hamsters: Relative contributions of the ovaries, adrenals and steroids. MORIN, L. P. and N. G. FORGER 529

Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. VAUPEL, D. B. and E. C. MORTON 539

Evidence that a behavioral augmentation following repeated amphetamine administration does not involve peripheral mechanisms. KUCZENSKI, R., D. S. SEGAL, S. B. WEINBERGER and R. G. BROWNE 547

Consistency in catecholamine and cortisol excretion in males and females. FORSMAN, L. and U. LUNDBERG 555

Increased intravenous drug self-administration during deprivation of other reinforcers. CARROLL, M. E. and I. N. BOE 563

Evidence for genetic correlation of hypnotic effects and cerebellar Purkinje neuron depression in response to ethanol in mice. SPUHLER, K., B. HOFFER, N. WEINER and M. PALMER ... 569

BRIEF COMMUNICATIONS

Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat. SINGER, G., M. WALLACE and R. HALL 579

A TRS-80-based system for the control of behavioral experiments. EMMETT-OGLESBY, M. W., D. G. SPENCER, JR. and D. E. ARNOULT 583

Lack of synergism and cross tolerance between tactile stimulus- and LSD-induced limb flicking in the cat. TRULSON, M. E. and T. CRISP 589

ANNOUNCEMENTS 593

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 4 OCTOBER 1982

CONTENTS

Time course analysis of para-chlorophenylalanine induced suppression of self-stimulation behavior. GRATTON, A. 597

Comparison of behavioral properties of di- and tri-methoxyphenylisopropylamines. GLENNON, R. A. and R. YOUNG 603

Induction of high voluntary ethanol intake in dependent rats. MARFAING-JALLAT, P. and J. LE MAGNEN 609

Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine. MUELLER, K., S. SABODA, R. PALMOUR and W. L. NYHAN 613

Rotational behavior produced by unilateral ventral noradrenergic bundle lesions: Evidence for a noradrenergic-dopaminergic interaction in the brain. PŁAŹNIK, A., O. PUCIŁOWSKI, W. KOSTOWSKI, A. BIDZIŃSKI and M. HAUPTMANN 619

Selective neurotoxin lesions of the lateral septum: Changes in social and aggressive behaviours. CLARKE, A. and S. E. FILE 623

Female reproduction during chronic ethanol consumption in rats. KRUEGER, W. A., W. J. BO and P. K. RUDEEN 629

Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats. VÉCSEI, L., G. TELEGDY, A. V. SCHALLY and D. H. COY 633

Enhanced neophobia but normal plasma corticosterone levels in rats with dorsal noradrenergic bundle lesions. MARTIN-IVERSON, M. T., M. PISA, E. CHAN and H. C. FIBIGER 639

A sensitive and selective monkey conflict test. PATEL, J. B. and B. MIGLER 645

An *in vivo* method for testing GABAergic compounds. FUNG, Y. K., A. NOVIN-BAHERAN, T. K. BOSH and D. R. GRASSMAN 651

Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome. GRANT, S. J. and D. E. REDMOND, JR. 655

Effect of early pre- and postnatal acquired malnutrition on development and sexual behavior in the rat. MENENDEZ-PATTERSON, A., S. FERNANDEZ, J. FLOREZ-LOZANO and B. MARÍN 659

Establishment of secondary reinforcement in sign tracking and place preference tests following pimozide treatment. TOMBAUGH, T. N., L. J. GRANDMAISON and K. A. ZITO 665

Discriminative stimulus properties of *d*-amphetamine in pigeons. JÄRBE, T. U. C. 671

Brain cyclic AMP and memory in mice. RANDT, C. T., M. E. JUDGE, K. A. BONNET and D. QUARTERMAIN 677

Dopaminergic antagonists do not block testosterone-induced decrease in luteinizing hormone. CHAPIN, R. E., G. R. BREESE and R. A. MUELLER 681

Structural requirements for neurohypophyseal peptide maintenance of ethanol tolerance. HOFFMAN, P. L. 685

Effects of opiate antagonists on social and aggressive behavior of isolated mice. PUGLISI-ALLEGRA, S., A. OLIVERIO and P. MANDEL 691

Attenuation of pentobarbital-elicited hypothermia in rats with a history of pentobarbital-LiCl pairings. TAUKULIS, H. K. 695

Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. QUIRION, R., M. A. BAYORH, R. L. ZERBE and C. B. PERT 699

Similarities of the cataleptic state induced by β-endorphin and morphine. RONDEAU, D. B., M. TURCOTTE, L. YOUNG and D. HEBERT 703

Generalization between benzodiazepine- and triazolopyridazine-elicited discriminative cues. McELROY, J. F. and R. S. FELDMAN 709

On the possible role of excitatory amino acids in the striatum in mediating morphine-induced muscular rigidity. TURSKI, L., U. HAVEMANN and K. KUSCHINSKY 715

Prenatal stress: Effects on brain biogenic amine and plasma corticosterone levels. PETERS, D. A. V. 721

Bethanechol-induced water intake in rats: Possible mechanisms of induction. FREGLY, M. J., D. C. KIKTA and J. E. GREENLEAF 727

Interaction between nicotine and endogenous opioid mechanisms in the unanesthetized dog. KAMERLING, S. G., J. G. WETTSTEIN, J. W. SLOAN, T.-P. SU and W. R. MARTIN 733

Drinking stimulation by a new angiotensin, crinia-angiotensin II, in rats and pigeons. CANTALAMESSA, F., G. DE CARO, M. MASSI and L. G. MICOSSI 741

Morphine enhances the release of ^{3}H-purines from rat brain cerebral cortical prisms. WU, P. H., J. W. PHILLIS and H. YUEN 749

Similar antagonism of morphine analgesia by MIF-1 and naloxone in *Carassius auratus*. EHRENSING, R. H., G. F. MICHELL and A. J. KASTIN 757

Effects of intravenous ethanol and of 4-methylpyrazole on alcohol drinking in alcohol-preferring rats. WALLER, M. B., W. J. McBRIDE, L. LUMENG and T.-K. LI 763

Does pimozide block the reinforcing effect of brain stimulation? GALLISTEL, C. R., M. BOYTIM, Y. GOMITA and L. KLEBANOFF 769

Pimozide blocks reinforcement but not priming from MFB stimulation in the rat. WASSERMAN, E. M., Y. GOMITA and C. R. GALLISTEL 783

Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. SHANNON, H. E. and T.-P. SU 789

TRH and its novel analog (DN-1417): Antipentobarbital action and involvement of cholinergic mechanisms. MIYAMOTO, M., Y. NAGAI, S. NARUMI, Y. SAJI and Y. NAGAWA .. 797

Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. MYERS, W. D., K. T. NG and G. SINGER 807

Ethanol and some tetrahydroisoquinolines alter the discharge of cortical and hippocampal neurons: Relationship to endogenous opioids. BERGER, T., E. D. FRENCH, G. R. SIGGINS, W. T. SHIER and F. E. BLOOM 813

A tethering system for intravenous and intragastric drug administration in the baboon. LUKAS, S. E., R. R. GRIFFITHS, L. D. BRADFORD, J. V. BRADY, L. DALEY and R. DELORENZO 823

Alcohol drinking in the rat: Increases following intracerebroventricular treatment with tetrahydro-β-carbolines. TUOMISTO, L., M. M. AIRAKSINEN, P. PEURA and C. J. P. ERIKSSON 831

BRIEF COMMUNICATIONS

Ergot drugs suppress plasma levels of prolactin (PRL) but not growth hormone (GH), luteinizing hormone (LH) or corticosterone (CORT) in parturient mice. MANN, M. A., S. D. MICHAEL and B. SVARE 837

Effects of reinforcement-blocking doses of pimozide on neural systems driven by rewarding stimulation of the MFB: A ^{14}C-2-deoxyglucose analysis. GOMITA, Y. and C. R. GALLISTEL 841

Role of serotonin in the blockade of muricidal behavior by tricyclic antidepressants. EISENSTEIN, N., L. C. IORIO and D. CLODY 847

A comparison of atropine, benztropine and diphenhydramine on the reversal of haloperidol induced suppression of self-stimulation. CAREY, R. J. 851

Biphasic dose-response effect of baclofen on haloperidol catalepsy in the rat. RICHARDSON, J. S. and A. K. RICHARDSON 855

Effects of paced coital stimulation on termination of estrus and brain indoleamine levels in female rats. ERSKINE, M. S. and M. J. BAUM 857

Effects of atropine methyl nitrate on sham feeding in the rat. WEINGARTEN, H. P. and S. D. WATSON 863

BOOKS RECEIVED 869

ANNOUNCEMENTS 870

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 5 NOVEMBER 1982

CONTENTS

A quantitative analysis of stereotyped gnawing induced by apomorphine. REDGRAVE, P., P. DEAN and G. LEWIS 873

Evidence for a serotonergic mechanism of the learned helplessness phenomenon. BROWN, L., R. A. ROSELLINI, O. B. SAMUELS and E. P. RILEY 877

Selective breeding for sensitivity to DFP: Generalization of effects beyond criterion variables. RUSSELL, R. W., D. H. OVERSTREET, M. MESSENGER and S. C. HELPS 885

Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycineamide. DAVIS, J. L., R. M. PICO and A. CHERKIN 893

Central and peripheral components of morphine mydriasis in mice. KORCZYN, A. D. and D. MAOR 897

Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. ROBERTS, D. C. S. and G. F. KOOB 901

Naloxone and play fighting in juvenile rats. BEATTY, W. W. and K. B. COSTELLO 905

Effects of sodium barbitone on learning and memory-storage of an appetitive and an aversive task. TOMAZ, C. A. B., D. F. VENTURA and J. R. LEITE 909

Effects of nicotine on the visual evoked response. WOODSON, P. P., K. BAETTIG, M. W. ETKIN, W. M. KALLMAN, G. J. HARRY, M. J. KALLMAN and J. A. ROSECRANS 915

Enhancement of osmotic- and hypovolemic-induced drinking by chlordiazepoxide in rats is blocked by naltrexone. COOPER, S. J. 921

Effects of prenatal and postnatal exposure of rats to alcohol: Changes in (Na^+-K^+) ATPase. GUERRI, C. and S. GRISOLÍA 927

Lesions of cholinergic forebrain nuclei: Changes in avoidance behavior and scopolamine actions. LO CONTE, G., L. BARTOLINI, F. CASAMENTI, I. MARCONCINI-PEPEU and G. PEPEU 933

Brain serotonergic activity and plasma amino acid levels in genetically obese Zucker rats. FINKELSTEIN, J. A., W. T. CHANCE and J. E. FISCHER 939

***p*-Chlorophenylalanine effects on shock-induced attack and pressing responses in rats.** SEWELL, R. G., J. A. GALLUS, F. P. GAULT and J. P. CLEARY 945

Dopaminergic properties of nomifensine. GIANUTSOS, G., G. MORROW, S. LIGHT and M. J. SWEENEY 951

Failure of rats deprived of water to increase food intake during glucoprivation induced by 2-deoxy-D-glucose. WATSON, P. J. and M. D. BIDERMAN 955

Open-field emotional reactivity and alcohol intake in rats. SATINDER, K. P. 961

Analysis of the difference in the behavioral effects of apomorphine in C57BL/6 and DBA/2 mice. VETULANI, J., M. SANSONE and A. OLIVERIO 967

Intra-raphe muscimol induced hyperactivity depends on ascending serotonin projections. SAINATI, S. M. and S. A. LORENS 973

An examination of methodological refinements, clozapine and fluphenazine in the anhedonia paradigm. FAUSTMAN, W. O. and S. C. FOWLER 987

Effects of piribedil on schedule-controlled responding of the pigeon. LEANDER, J. D. 995

Effects of PAM, proPAM, and DFP on behavior, thermoregulation, and brain AChE in rats. KENLEY, R. A., R. A. HOWD and E. T. UYENO 1001

Delta sleep-inducing peptide crosses the blood-brain-barrier in dogs: Some correlations with protein binding. BANKS, W. A., A. J. KASTIN and D. H. COY 1009

Apomorphine-induced facilitation of intracranial self-stimulation following dopamine denervation of the nucleus accumbens. STRECKER, R. E., D. C. S. ROBERTS and G. F. KOOB 1015

Extent and control of shock affects naltrexone sensitivity of stress-induced analgesia and reactivity to morphine. HYSON, R. L., L. J. ASHCRAFT, R. C. DRUGAN, J. W. GRAU and S. F. MAIER 1019

Estrogen and haloperidol-induced versus handling-related catalepsy in male rats. DE RYCK, M., R. E. HRUSKA and E. K. SILBERGELD 1027

Ethanol intoxication and withdrawal among three age groups of C57BL/6NNIA mice. WOOD, W. G., H. J. ARMBRECHT and R. W. WISE 1037

Delay of cancer anorexia following the intraventricular injection of para-Chlorophenylalanine. CHANCE, W. T., M. VON MEYENFELDT and J. E. FISCHER 1043

Effects of clozapine, haloperidol and thiothixene on schedule-controlled responding and schedule-induced eating and drinking of rabbits. BARRETT, J. E. 1049

Intravenous diazepam in humans: Effects on acquisition and performance of response chains. DESJARDINS, P. J., J. M. MOERSCHBAECHER, D. M. THOMPSON and J. R. THOMAS 1055

Failure to find electrophysiological correlates of chronic neuroleptic-induced oral dyskinesias in cats: Somatosensory and substantia nigra evoked potentials, electroencephalogram, and caudate spindles. GLASSMAN, R. B., H. N. GLASSMAN and B. M. BALTRUS 1061

Cyclic AMP and cyclic GMP response to stress in brain and pituitary: Stress elevates pituitary cyclic AMP. KANT, G. J., J. L. MEYERHOFF, B. N. BUNNELL and R. H. LENOX 1067

Does tolerance develop to the activating, as well as the depressant, effects of ethanol? TABAKOFF, B. and K. KIIANMAA 1073

Sex-dependent biological changes following prenatal nicotine exposure in the rat. PETERS, D. A. V. and S. TANG 1077

Failure of naloxone or MIF-1 to reverse ischemic-induced neurologic deficits in gerbils. KASTIN, A. J., C. NISSEN and R. D. OLSON 1083

Comparative lethality of coca and cocaine. BEDFORD, J. A., C. E. TURNER and H. N. ELSOHLY 1087

Intragastric methylphenidate does have effects on the behavior of rats. FOLTIN, R. W. 1089

ANNOUNCEMENTS 1091

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 17 NUMBER 6 DECEMBER 1982

CONTENTS

Brain stimulation as the reinforcer in alcohol-saline discrimination. DEWITTE, PH. 1093

Reduced preference for alcohol during pregnancy and following lactation in rats. MEANS, L. W. and H. B. GOY 1097

Acute effects of ethanol and acetaldehyde on blood pressure and heart rate in disulfiram-treated and control rats. HELLSTRÖM, E. and O. TOTTMAR 1103

Bidirectional transfer of intracerebrally administered pentylenetetrazol and electrical kindling. CAIN, D. P. 1111

Dopamine receptors in the striatum and limbic system of various strains of mice: Relation to differences in responses to apomorphine. MICHALUK, J., L. ANTKIEWICZ-MICHALUK, A. ROKOSZ-PELC, M. SANSONE, A. OLIVERIO and J. VETULANI 1115

Disruption of passive avoidance memory by REM sleep deprivation: Methodological and pharmacological considerations. HARRIS, P. F., D. H. OVERSTREET and J. ORBACH 1119

Effects of DDAVP, a vasopressin analog, on delayed matching behavior in the pigeon. TEAL, J. J. and H. L. EVANS 1123

Learned taste aversion to saccharin following intraventricular or intraperitoneal administration of d,l-amphetamine. GREENSHAW, A. J. and O. BUREŠOVÁ 1129

Anorexic properties of three monoamine oxidase inhibitors. WILLIS, G. L. and G. C. SMITH 1135

Concerning the specificity of the hypothalamic opiate receptor responsible for food intake in the rat. TEPPERMAN, F. S. and M. HIRST 1141

Inhibition of acute feeding responses to systemic 2-deoxyglucose or insulin in rats pretreated with the GABA-transaminase blocker ethanolamine-O-sulfate (EOS). NOBREGA, J. and D. V. COSCINA 1145

Reduced prolactin binding to liver membranes during pheromonal emission in the rat. LEE, T. M., B. HALPERN, C. LEE and H. MOLTZ 1149

Neuropharmacological profile of R 18 503-induced wet-shake behaviour in the rat: Noradrenergic and opiate components. ASHTON, D. and A. WAUQUIER 1155

Enhanced analgesic response to morphine in adult rats exposed to morphine prenatally. KIRBY, M. L., S. E. DEROSSETT and S. G. HOLTZMAN 1161

Chlordiazepoxide-induced ataxia, muscle relaxation and sedation in the rat: Effects of muscimol, picrotoxin and naloxone. FILE, S. E. 1165

Onset and offset of the diazepam stimulus complex. HAUG, T. and K. G. GÖTESTAM 1171

Naloxazone and pain-inhibitory systems: Evidence for a collateral inhibition model. KIRCHGESSNER, A. L., R. J. BODNAR and G. W. PASTERNAK 1175

Opiate effects on social investigatory behavior of male mice. LANDAUER, M. R. and R. L. BALSTER 1181

Differential penetration of DSIP peptides into rat brain. KASTIN, A. J., W. A. BANKS, P. F. CASTELLANOS, C. NISSEN and D. H. COY 1187

Characterization of binding sites for N-Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH_2) in rat brain. ZADINA, J., A. J. KASTIN, E. F. KRIEG JR. and D. H. COY 1193

Limitations to effect of α-MSH on permeability of blood-brain barrier to IV ^{99m}Tc-pertechnetate. KASTIN, A. J. and L. A. FABRE 1199

Opposite effects of CRF and ACTH on reserpine-induced hypothermia. KASTIN, A. J., L. C. HONOUR, J. SUEIRAS-DIAZ and D. H. COY 1203

Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. FENTON, H. M. and J. M. LIEBMAN 1207

Morphine analgesia and tolerance in the tail-flick and formalin tests: Dose-response relationships. ABBOTT, F. V., R. MELZACK and B. F. LEBER 1213

The acute effects of amitriptyline, iprindole and trazodone on blood pressure and heart rate in rats. RICHARDSON, J. S. and E. K. Y. CHIU 1221

Prednisolone effects upon body and organ weights, water intake, and several behaviors. SEWELL, R. G., J. A. GALLUS and K. P. NANRY 1225

Prostaglandin inhibition of apomorphine-induced circling in mice. SCHWARZ, R. D., N. J. URETSKY and J. R. BIANCHINE 1233

Dissociation of tolerance and physical dependence after ethanol/chlordiazepoxide intake. CHAN, A. W. K., D. L. SCHANLEY, F. W. LEONG and D. CASBEER 1239

Avoidance performance, cue and response-choice discrimination after neuroleptic treatment. ANISMAN, H., A. CORRADINI, T. N. TOMBAUGH and R. ZACHARKO 1245

Circadian variation in methamphetamine- and apomorphine-induced increase in ambulatory activity in mice. KURIBARA, H. and S. TADOKORO 1251

Modulation of long-term potentiation: Effects of adrenergic and neuroleptic drugs. DUNWIDDIE, T. V., N. L. ROBERSON and T. WORTH 1257

Effect of D- and/or L-aspartic acids on feeding, drinking, urine outflow and core temperature. KOYUNCUOĞLU, H. and K. BERKMAN 1265

Hibernation "trigger": Opioid-like inhibitory action on brain function of the monkey. OELTGEN, P. R., J. W. WALSH, S. R. HAMANN, D. C. RANDALL, W. A. SPURRIER and R. D. MYERS 1271

Effects of opiate antagonists and putative mu- and kappa-agonists on milk intake in rat and squirrel monkey. LOCKE, K. W., D. R. BROWN and S. G. HOLTZMAN 1275

BRIEF COMMUNICATIONS

Effects of apomorphine on appetitive conditioning in 6-hydroxydopamine treated rat pups. WELDON, D. A., R. S. WOOL, M. H. TEICHER, B. A. SHAYWITZ, D. J. COHEN and G. M. ANDERSON 1281

Pharmacological responses of the microvasculature of transplanted cardiac tissue. CORNISH, K. G., W. L. JOYNER and J. P. GILMORE 1285

Effects of naloxone and its quarternary form on fluid consumption in rats. HEMMER, R. C., G. A. OLSON, A. J. KASTIN, J. H. McLEAN and R. D. OLSON 1287

Alterations in trace amine and trace acid concentrations in isolated aggressive mice. DOURISH, C. T., B. A. DAVIS, L. E. DYCK, R. S. G. JONES and A. A. BOULTON 1291

Effects of haloperidol and physostigmine on self-administration of local anesthetics. GARZA, R. DE LA and C. E. JOHANSON 1295

MIF-1 does not act like naloxone in antagonizing the cardiovascular activity of leucine-enkephalin in the conscious dog. SANDER, G. E., A. J. KASTIN and T. D. GILES 1301

Implications for multiple transmitter mediation in amphetamine-induced stereotypies. CHEAL, M. L., M. E. KURKULOS and L. SILVA 1305

Antiapomorphine and locomotor effects of neuroleptics in rhesus monkeys. PROSOLT, R. D., S. ROUX and M. JALFRE 1309

Acute effects of alcohol on photic evoked potentials of albino rats: Visual cortex and superior colliculus. HETZLER, B. E., K. E. OAKLAY, R. L. HEILBRONNER and T. VESTAL 1313

Inhibition by lithium of β-endorphin-induced psychomotor excitation in cats. BELESLIN, D. B., R. SAMARDŽIĆ and S. K. KRSTIĆ 1317

INDEX TO VOLUME 17 1321

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

Dopamine Receptors and Their Behavioral Correlates

Supplement to *PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR*

CONTENTS

Introduction. WAYNER, M. J. v

Dopamine autoreceptor stimulation: Clinical significance. MELTZER, H. Y. 1

Structure activity relationships of presynaptic dopamine receptor agonists. BHATNAGER, R. K., S. P. ARNERIĆ, J. G. CANNON, J. FLYNN and J. P. LONG 11

Stress and its timing: Critical factors in determining the consequences of dopaminergic agents. ANTELMAN, S. 21

Dopamine and antianxiety activity. TAYLOR, D. P., L. A. RIBLET, H. C. STANTON, A. S. EISON, M. S. EISON and D. L. TEMPLE, JR. 25

Comparative neuropharmacology of antianxiety drugs. PAUL, S. M. and P. SKOLNICK 37

Nutritional iron and dopamine binding sites in the rat brain. ASHKENAZI, R., D. BEN-SHACHAR and M. B. H. YOUDIM 43

Subject Index 49